

Azeem Latib

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1933459/publications.pdf>

Version: 2024-02-01

774
papers

25,483
citations

6613

79
h-index

12946

131
g-index

884
all docs

884
docs citations

884
times ranked

11788
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcatheter Aortic Valve Implantation in Failed Bioprosthetic Surgical Valves. JAMA - Journal of the American Medical Association, 2014, 312, 162.	7.4	762
2	Incidence, Predictors, and Outcomes of Aortic Regurgitation After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2013, 61, 1585-1595.	2.8	702
3	Anatomical and Procedural Features Associated With Aortic Root Rupture During Balloon-Expandable Transcatheter Aortic Valve Replacement. Circulation, 2013, 128, 244-253.	1.6	476
4	Randomized Study of the Crush Technique Versus Provisional Side-Branch Stenting in True Coronary Bifurcations. Circulation, 2009, 119, 71-78.	1.6	472
5	Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment. Circulation, 2007, 116, 745-754.	1.6	430
6	Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention, 2015, 10, 1144-1153.	3.2	411
7	Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis. Journal of the American College of Cardiology, 2017, 69, 2579-2589.	2.8	356
8	Transcatheter Treatment of Severe Tricuspid Regurgitation With the Edge-to-Edge MitraClip Technique. Circulation, 2017, 135, 1802-1814.	1.6	313
9	Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation. Journal of the American College of Cardiology, 2019, 74, 2998-3008.	2.8	302
10	A Randomized Multicenter Study Comparing a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels. Journal of the American College of Cardiology, 2012, 60, 2473-2480.	2.8	280
11	Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. European Heart Journal, 2019, 40, 441-451.	2.2	271
12	Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. European Heart Journal, 2018, 39, 687-695.	2.2	269
13	European expert consensus on rotational atherectomy. EuroIntervention, 2015, 11, 30-36.	3.2	247
14	Outcomes After Current Transcatheter Tricuspid Valve Intervention. JACC: Cardiovascular Interventions, 2019, 12, 155-165.	2.9	246
15	Treatment and Clinical Outcomes of Transcatheter Heart Valve Thrombosis. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	244
16	Management of Conduction Disturbances Associated With Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 1086-1106.	2.8	242
17	Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death. JAMA - Journal of the American Medical Association, 2016, 316, 1083.	7.4	241
18	Management and Long-Term Prognosis of Spontaneous Coronary Artery Dissection. American Journal of Cardiology, 2015, 116, 66-73.	1.6	230

#	ARTICLE	IF	CITATIONS
19	Bifurcation Disease. JACC: Cardiovascular Interventions, 2008, 1, 218-226.	2.9	225
20	Drug-Coated Balloons for Coronary Artery Disease. JACC: Cardiovascular Interventions, 2020, 13, 1391-1402.	2.9	218
21	Transcatheter Tricuspid Valve Interventions. Journal of the American College of Cardiology, 2018, 71, 2935-2956.	2.8	214
22	A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial. American Heart Journal, 2013, 165, 65-72.	2.7	212
23	Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation. Journal of the American College of Cardiology, 2017, 70, 2752-2763.	2.8	207
24	Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. New England Journal of Medicine, 2020, 382, 1208-1218.	27.0	207
25	Transcatheter Therapies for Treating Tricuspid Regurgitation. Journal of the American College of Cardiology, 2016, 67, 1829-1845.	2.8	189
26	Predictors of Left Ventricular Outflow Tract Obstruction After Transcatheter Mitral Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 182-193.	2.9	186
27	5-Year Outcomes After Transcatheter Aortic Valve Implantation With CoreValve Prosthesis. JACC: Cardiovascular Interventions, 2015, 8, 1084-1091.	2.9	184
28	Transcatheter Mitral Valve Replacement for Degenerated Bioprosthetic Valves and Failed Annuloplasty Rings. Journal of the American College of Cardiology, 2017, 70, 1121-1131.	2.8	183
29	Transcatheter Aortic Valve Replacement With Early- and New-Generation Devices in Bicuspid Aortic Valve Stenosis. Journal of the American College of Cardiology, 2016, 68, 1195-1205.	2.8	177
30	Transcatheter Aortic Valve Implantation With the Edwards SAPIEN Versus the Medtronic CoreValve Revalving System Devices. Journal of the American College of Cardiology, 2013, 61, 830-836.	2.8	176
31	The International Multicenter TriValve Registry. JACC: Cardiovascular Interventions, 2017, 10, 1982-1990.	2.9	175
32	A Bicuspid Aortic Valve Imaging Classification for the TAVR Era. JACC: Cardiovascular Imaging, 2016, 9, 1145-1158.	5.3	174
33	6-Month Outcomes of Tricuspid Valve Reconstruction for Patients With Severe Tricuspid Regurgitation. Journal of the American College of Cardiology, 2019, 73, 1905-1915.	2.8	172
34	Incidence, Predictors, Management, Immediate and Long-Term Outcomes Following Grade III Coronary Perforation. JACC: Cardiovascular Interventions, 2011, 4, 87-95.	2.9	170
35	Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2018, 71, 1513-1524.	2.8	170
36	1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 2019, 12, 1451-1461.	2.9	160

#	ARTICLE	IF	CITATIONS
37	Prospective Multicenter Evaluation of the DirectÂFlow Medical Transcatheter Aortic Valve. Journal of the American College of Cardiology, 2014, 63, 763-768.	2.8	151
38	Clinical Impact of Persistent Left Bundle-Branch Block After Transcatheter Aortic Valve Implantation With CoreValve Revalving System. Circulation, 2013, 127, 1300-1307.	1.6	141
39	Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction. Journal of the American College of Cardiology, 2020, 75, 1882-1893.	2.8	140
40	5-Year Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Lesions. JACC: Cardiovascular Interventions, 2010, 3, 595-601.	2.9	136
41	Comparison of vascular closure devices for access site closure after transfemoral aortic valve implantation. European Heart Journal, 2015, 36, 3370-3379.	2.2	133
42	Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes. European Heart Journal, 2019, 40, 466-472.	2.2	133
43	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention, 2015, 11, 45-52.	3.2	131
44	Long-Term Outcomes in Patients WithÂNew Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 301-310.	2.9	130
45	Transcatheter aortic valve implantation: current status and future perspectives. European Heart Journal, 2018, 39, 2625-2634.	2.2	130
46	Transcatheter Mitral Annuloplasty in Chronic Functional Mitral Regurgitation. JACC: Cardiovascular Interventions, 2016, 9, 2039-2047.	2.9	129
47	Transcatheter Valve Repair for PatientsÂWith Mitral Regurgitation. JACC: Cardiovascular Interventions, 2019, 12, 1369-1378.	2.9	128
48	Predictors of moderateÂtoÂsevere paravalvular aortic regurgitation immediately after corevalve implantation and the impact of postdilatation. Catheterization and Cardiovascular Interventions, 2011, 78, 432-443.	1.7	125
49	Outcomes After Transcatheter Aortic Valve Implantation With Both Edwards-SAPIEN and CoreValve Devices in a Single Center. JACC: Cardiovascular Interventions, 2010, 3, 1110-1121.	2.9	124
50	A new technique for vascular access management in transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2010, 75, 784-793.	1.7	123
51	Excimer Laser LEsion Modification to Expand Non-dilatable sTents: The ELLEMENT Registry. Cardiovascular Revascularization Medicine, 2014, 15, 8-12.	0.8	122
52	Drug-Eluting Stent for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 718-727.	2.9	121
53	Comparison of Incidence and Predictors of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation Using the CoreValve Versus the Edwards Valve. American Journal of Cardiology, 2013, 112, 554-559.	1.6	118
54	Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses. JACC: Cardiovascular Interventions, 2017, 10, 1048-1056.	2.9	117

#	ARTICLE	IF	CITATIONS
55	Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. EuroIntervention, 2017, 12, 2110-2117.	3.2	114
56	Interplay Between Mitral Regurgitation and Transcatheter Aortic Valve Replacement With the CoreValve Revalving System. Circulation, 2013, 128, 2145-2153.	1.6	113
57	Transcatheter vs surgical aortic valve replacement in intermediate-surgical-risk patients with aortic stenosis: A propensity score-matched case-control study. American Heart Journal, 2012, 164, 910-917.	2.7	111
58	First-in-Man Implantation of a Tricuspid Annular Remodeling Device for Functional Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 2015, 8, e211-e214.	2.9	111
59	Subintimal tracking and re-entry technique with contrast guidanc: A safer approach. Catheterization and Cardiovascular Interventions, 2008, 72, 790-796.	1.7	105
60	Transcatheter Replacement of Failed Bioprosthetic Valves. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	104
61	Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration. European Heart Journal, 2019, 40, 456-465.	2.2	100
62	Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention, 2021, 16, e1264-e1271.	3.2	100
63	Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. European Heart Journal, 2008, 29, 2108-2115.	2.2	99
64	Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. European Heart Journal, 2020, 41, 2731-2742.	2.2	97
65	Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. EuroIntervention, 2014, 10, 746-752.	3.2	97
66	Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair. Journal of the American College of Cardiology, 2022, 79, 448-461.	2.8	96
67	Bifurcation stenting: current strategies and new devices. Heart, 2009, 95, 495-504.	2.9	95
68	Percutaneous Plug-Based Arteriotomy Closure Device for Large-Bore Access. JACC: Cardiovascular Interventions, 2017, 10, 613-619.	2.9	93
69	Incidence, Management, and Outcomes of Cardiac Tamponade During Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Interventions, 2012, 5, 1264-1272.	2.9	91
70	The impact of calcium volume and distribution in aortic root injury related to balloon-expandable transcatheter aortic valve replacement. Journal of Cardiovascular Computed Tomography, 2015, 9, 382-392.	1.3	91
71	Impact of Pre-Existing Prosthesis-Patient Mismatch on Survival Following Aortic Valve-in-Valve Procedures. JACC: Cardiovascular Interventions, 2018, 11, 133-141.	2.9	91
72	Chimney Stenting for Coronary Occlusion During TAVR. JACC: Cardiovascular Interventions, 2020, 13, 751-761.	2.9	90

#	ARTICLE	IF	CITATIONS
73	Accuracy of intravascular ultrasound and optical coherence tomography in identifying functionally significant coronary stenosis according to vessel diameter: A meta-analysis of 2,581 patients and 2,807 lesions. American Heart Journal, 2015, 169, 663-673.	2.7	88
74	Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Stent Implantation in Patients Taking Chronic Oral Anticoagulation. JACC: Cardiovascular Interventions, 2008, 1, 56-61.	2.9	85
75	CoreValve implantation for severe aortic regurgitation: a multicentre registry. EuroIntervention, 2014, 10, 739-745.	3.2	85
76	Outcomes of Redo Transcatheter Aortic Valve Replacement for the Treatment of Postprocedural and Late Occurrence of Paravalvular Regurgitation and Transcatheter Valve Failure. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	83
77	Outcomes in Patients With Transcatheter Aortic Valve Replacement and Left Main Stenting. Journal of the American College of Cardiology, 2016, 67, 951-960.	2.8	83
78	Mid-Term Valve-Related Outcomes After Transcatheter Tricuspid Valve-in-Valve or Valve-in-Ring Replacement. Journal of the American College of Cardiology, 2019, 73, 148-157.	2.8	83
79	TAVR-Associated Prosthetic Valve Infective Endocarditis. Journal of the American College of Cardiology, 2014, 64, 2176-2178.	2.8	82
80	Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2014, 114, 1447-1455.	1.6	82
81	Transcatheter aortic valve implantation in patients with bicuspid aortic valve: A patient level multi-center analysis. International Journal of Cardiology, 2015, 189, 282-288.	1.7	82
82	Transcatheter Valve-in-Ring Implantation for the Treatment of Residual or Recurrent Tricuspid Valve Dysfunction After Prior Surgical Repair. JACC: Cardiovascular Interventions, 2017, 10, 53-63.	2.9	81
83	Routine Screening of Coronary Artery Disease With Computed Tomographic Coronary Angiography in Place of Invasive Coronary Angiography in Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2015, 8, e002025.	3.9	80
84	The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIEN ³ and Medtronic CoreValve ReValving System [®] devices: the Milan registry. EuroIntervention, 2011, 7, 556-563.	3.2	80
85	Comparison of Results of Transcatheter Aortic Valve Implantation in Patients With Severely Stenotic Bicuspid Versus Tricuspid or Nonbicuspid Valves. American Journal of Cardiology, 2014, 113, 1390-1393.	1.6	79
86	Mechanism and Implications of the Tricuspid Regurgitation. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	79
87	Early Multinational Experience of Transcatheter Tricuspid Valve Replacement for Treating Severe Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 2020, 13, 2482-2493.	2.9	79
88	Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Heart, 2018, 104, 306-312.	2.9	77
89	Predictors of Advanced Conduction Disturbances Requiring a Late (>48 H) Permanent Pacemaker Following Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1519-1526.	2.9	77
90	3-Year Follow-Up of the Balloon Elution and Late Loss Optimization Study (BELLO). JACC: Cardiovascular Interventions, 2015, 8, 1132-1134.	2.9	74

#	ARTICLE	IF	CITATIONS
91	Predictors of cardiac death in patients with coronary chronic total occlusion not revascularized by PCI. International Journal of Cardiology, 2013, 168, 1402-1409.	1.7	73
92	Heyde's Syndrome Incidence and Outcome in Patients Undergoing Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2013, 61, 687-689.	2.8	73
93	Machine Learning Prediction Models for In-Hospital Mortality After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 1328-1338.	2.9	73
94	Coronary chronic total occlusions. Catheterization and Cardiovascular Interventions, 2012, 79, 20-27.	1.7	71
95	Sex Differences in Transfemoral Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 2758-2767.	2.8	71
96	Predictors, Incidence, and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation Complicated by Stroke. Circulation: Cardiovascular Interventions, 2019, 12, e007546.	3.9	71
97	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. Journal of the American College of Cardiology, 2020, 75, 1017-1028.	2.8	70
98	Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome. Journal of the American College of Cardiology, 2018, 72, 2886-2903.	2.8	68
99	1-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study. JACC: Cardiovascular Interventions, 2020, 13, 2344-2357.	2.9	68
100	Long-Term Outcomes After the Percutaneous Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions, 2011, 4, 155-164.	2.9	66
101	Silent cerebral injury after transcatheter aortic valve implantation and the preventive role of embolic protection devices: A systematic review and meta-analysis. International Journal of Cardiology, 2016, 221, 97-106.	1.7	66
102	Coronary Access After TAVR-in-TAVR as Evaluated by Multidetector Computed Tomography. JACC: Cardiovascular Interventions, 2020, 13, 2528-2538.	2.9	65
103	Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation. American Heart Journal, 2016, 173, 77-85.	2.7	64
104	Tricuspid annuloplasty versus a conservative approach in patients with functional tricuspid regurgitation undergoing left-sided heart valve surgery: A study-level meta-analysis. International Journal of Cardiology, 2017, 240, 138-144.	1.7	64
105	A Practical Approach to the Management of Complications During Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 1797-1810.	2.9	64
106	Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses. Journal of the American College of Cardiology, 2021, 77, 1-14.	2.8	64
107	Periprocedural and Short-Term Outcomes of Transfemoral Transcatheter Aortic Valve Implantation With the Sapien XT as Compared With the Edwards Sapien Valve. JACC: Cardiovascular Interventions, 2011, 4, 743-750.	2.9	62
108	Conventional surgery and transcatheter closure via surgical transapical approach for paravalvular leak repair in high-risk patients: results from a single-centre experience. European Heart Journal Cardiovascular Imaging, 2014, 15, 1161-1167.	1.2	62

#	ARTICLE	IF	CITATIONS
109	Balloon Versus Self-Expandable Valve for the Treatment of Bicuspid Aortic Valve Stenosis. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008714.	3.9	62
110	High-Sensitivity C-Reactive Protein Is Within Normal Levels at the Very Onset of First ST-Segment Elevation Acute Myocardial Infarction in 41% of Cases. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2654-2661.	2.8	61
111	Long-Term Outcomes in Patients With New-Onset Persistent Left Bundle Branch Block Following TAVR. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1175-1184.	2.9	60
112	Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 433-443.	2.9	59
113	Clinical outcomes of a real-world cohort following bioresorbable vascular scaffold implantation utilising an optimised implantation strategy. <i>EuroIntervention</i> , 2017, 12, 1730-1737.	3.2	58
114	Computed tomography-based evaluation of aortic annulus, prosthesis size and impact on early residual aortic regurgitation after transcatheter aortic valve implantation. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 43, 43-51.	1.4	57
115	Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2088-2101.	2.8	57
116	Patient selection, echocardiographic screening and treatment strategies for interventional tricuspid repair using the edge-to-edge repair technique. <i>EuroIntervention</i> , 2018, 14, 645-653.	3.2	55
117	Acute kidney injury after transcatheter aortic valve implantation with self-expanding CoreValve prosthesis: results from a large multicentre Italian research project. <i>EuroIntervention</i> , 2014, 10, 133-140.	3.2	55
118	Long-Term Follow-Up on a Large Cohort of "Full-Metal Jacket" Percutaneous Coronary Intervention Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 416-422.	3.9	54
119	Histopathology of Clinical Coronary Restenosis in Drug-Eluting Versus Bare Metal Stents. <i>American Journal of Cardiology</i> , 2009, 104, 1660-1667.	1.6	54
120	Transcatheter Self-Expandable Valve Implantation for Aortic Stenosis in Small Aortic Annuli. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 196-206.	2.9	54
121	Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, E10-E15.	1.7	53
122	Transcatheter Aortic Valve Replacement in Oncology Patients With Severe Aortic Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 78-86.	2.9	53
123	Multimodality imaging of the tricuspid valve with implication for percutaneous repair approaches. <i>Heart</i> , 2017, 103, 1073-1081.	2.9	52
124	Full percutaneous biventricular support with two Impella pumps: the BiPella approach. <i>ESC Heart Failure</i> , 2018, 5, 368-371.	3.1	52
125	TAVI and Post Procedural Cardiac Conduction Abnormalities. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 85.	2.4	52
126	Value of Echocardiographic Right Ventricular and Pulmonary Pressure Assessment in Predicting Transcatheter Tricuspid Repair Outcome. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1251-1261.	2.9	52

#	ARTICLE	IF	CITATIONS
127	Clinical features, survival experience, and profile of plakophylin-2 gene mutations in participants of the Arrhythmogenic Right Ventricular Cardiomyopathy Registry of South Africa. <i>Heart Rhythm</i> , 2009, 6, S10-S17.	0.7	51
128	A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study. <i>International Journal of Cardiology</i> , 2015, 184, 17-21.	1.7	51
129	Clinical Valve Thrombosis After Transcatheter Aortic Valve-in-Valve Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006730.	3.9	51
130	Update on the Current Landscape of Transcatheter Options for Tricuspid Regurgitation Treatment. <i>Interventional Cardiology Review</i> , 2019, 14, 54-61.	1.6	50
131	CTO recanalization by intraocclusion injection of contrast: The microchannel technique. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 20-26.	1.7	49
132	Refractory Angina. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1-19.	2.9	49
133	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009565.	3.9	49
134	In-hospital and midterm clinical outcomes of rotational atherectomy followed by stent implantation: the ROTATE multicentre registry. <i>EuroIntervention</i> , 2016, 12, 1448-1456.	3.2	49
135	Afterload Mismatch After MitraClip Insertion for Functional Mitral Regurgitation. <i>American Journal of Cardiology</i> , 2014, 113, 1844-1850.	1.6	48
136	Impact of Balloon Post-Dilation on Clinical Outcomes After Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Prosthesis. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1014-1021.	2.9	47
137	Safety and efficacy of rotational atherectomy for the treatment of undilatable underexpanded stents implanted in calcific lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, E19-E24.	1.7	47
138	New generation bioresorbable scaffold technologies: an update on novel devices and clinical results. <i>Journal of Thoracic Disease</i> , 2017, 9, S979-S985.	1.4	47
139	Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation. <i>American Journal of Cardiology</i> , 2018, 122, 1028-1035.	1.6	47
140	The Utility of Rapid Atrial Pacing Immediately Post-TAVR to Predict the Need for Pacemaker Implantation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1046-1054.	2.9	47
141	Transcatheter subclavian versus transapical access for transcatheter aortic valve implantation: A multicenter study. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 332-338.	1.7	46
142	Transcatheter Mitral Valve Replacement in the Transcatheter Aortic Valve Replacement Era. <i>Journal of the American Heart Association</i> , 2019, 8, e013352.	3.7	46
143	Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?. <i>Thrombosis Journal</i> , 2009, 7, 4.	2.1	45
144	Clinical and Angiographic Outcomes After Percutaneous Recanalization of Chronic Total Saphenous Vein Graft Occlusion Using Modern Techniques. <i>American Journal of Cardiology</i> , 2010, 106, 1721-1727.	1.6	45

#	ARTICLE	IF	CITATIONS
145	Percutaneous Direct Annuloplasty With Cardioband to Treat Recurrent Mitral Regurgitation After MitraClip Implantation. JACC: Cardiovascular Interventions, 2016, 9, e191-e192.	2.9	45
146	Coronary Access After Repeated Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Imaging, 2020, 13, 508-515.	5.3	45
147	Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis. European Heart Journal, 2020, 41, 1876-1886.	2.2	45
148	Anaesthetic management of transcatheter aortic valve implantation: results from the Italian CoreValve registry. EuroIntervention, 2016, 12, 381-388.	3.2	45
149	Reversible Edwards Sapien XT Dysfunction Due to Prosthesis Thrombosis Presenting as Early Structural Deterioration. Journal of the American College of Cardiology, 2013, 61, 787-789.	2.8	44
150	Impact of Strut Width in Periprocedural Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 900-909.	2.9	44
151	Drug-Coated Balloons Versus Second-Generation Drug-Eluting Stents for the Management of Recurrent Multimetall-Layered In-Stent Restenosis. JACC: Cardiovascular Interventions, 2015, 8, 1586-1594.	2.9	43
152	Outcomes of Transcatheter Tricuspid Valve-in-Valve Implantation in Patients With Ebstein Anomaly. American Journal of Cardiology, 2018, 121, 262-268.	1.6	43
153	Uncertainties and challenges in surgical and transcatheter tricuspid valve therapy: a state-of-the-art expert review. European Heart Journal, 2020, 41, 1932-1940.	2.2	43
154	ROTational ATHERectomy in acute coronary syndrome: early and midterm outcomes from a multicentre registry. EuroIntervention, 2016, 12, 1457-1464.	3.2	43
155	Transcatheter valve-in-valve implantation with the Edwards SAPIEN in patients with bioprosthetic heart valve failure: the Milan experience. EuroIntervention, 2012, 7, 1275-1284.	3.2	43
156	Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina. JACC: Cardiovascular Interventions, 2018, 11, 784-792.	2.9	42
157	Incidence, predictors and cerebrovascular consequences of leaflet thrombosis after transcatheter aortic valve implantation: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2019, 56, 488-494.	1.4	42
158	Impact of Massive or Torrential Tricuspid Regurgitation in Patients Undergoing Transcatheter Tricuspid Valve Intervention. JACC: Cardiovascular Interventions, 2020, 13, 1999-2009.	2.9	42
159	De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2021, 78, 763-777.	2.8	42
160	Rotational Atherectomy: A Contemporary Appraisal. Interventional Cardiology Review, 2019, 14, 182-189.	1.6	42
161	The Role of Drug-Eluting Balloons Alone or in Combination With Drug-Eluting Stents in the Treatment of De Novo Diffuse Coronary Disease. JACC: Cardiovascular Interventions, 2013, 6, 1153-1159.	2.9	41
162	New devices for TAVI: technologies and initial clinical experiences. Nature Reviews Cardiology, 2014, 11, 157-167.	13.7	41

#	ARTICLE	IF	CITATIONS
163	Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis. <i>EuroIntervention</i> , 2021, 17, e343-e352.	3.2	41
164	Long-Term Follow-Up of Drug-Eluting Stents When Inserted for On- and Off-Label Indications. <i>American Journal of Cardiology</i> , 2007, 100, 1619-1624.	1.6	40
165	Predictors and Clinical Impact of Prosthesis-Patient Mismatch After Self-Expandable TAVR in Small Annuli. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1218-1228.	2.9	40
166	2-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1538-1548.	2.9	40
167	First-in-Man Transseptal Implantation of a "Surgical-Like" Mitral Valve Annuloplasty Device for Functional Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1326-1328.	2.9	39
168	Rotational atherectomy in very long lesions: Results for the ROTATE registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E164-E172.	1.7	39
169	Percutaneous left atrial appendage occlusion in patients with atrial fibrillation and left appendage thrombus: feasibility, safety and clinical efficacy. <i>EuroIntervention</i> , 2018, 13, 1595-1602.	3.2	39
170	Planned versus provisional rotational atherectomy for severe calcified coronary lesions: Insights From the ROTATE multicenter registry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 881-889.	1.7	38
171	Usefulness of Predilation Before Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2016, 118, 107-112.	1.6	38
172	Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 15-21.	1.7	37
173	Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 949-957.	0.5	37
174	Treatment of the chronic total occlusion: A call to action for the interventional community. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 771-778.	1.7	37
175	Transcatheter aortic valve implantation with the new repositionable self-expandable Evolut R versus CoreValve system: A case-matched comparison. <i>International Journal of Cardiology</i> , 2017, 243, 126-131.	1.7	37
176	Outcomes After Transcatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Anatomy. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2144-2155.	2.9	37
177	Causes and timing of death during long-term follow-up after transcatheter aortic valve replacement. <i>American Heart Journal</i> , 2014, 168, 798-806.	2.7	36
178	Transfemoral Implantation of a Fully Repositionable and Retrievable Transcatheter Valve for Noncalcified Pure Aortic Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1842-1849.	2.9	36
179	Single-Antiplatelet Therapy in Patients with Contraindication to Dual-Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2017, 119, 1088-1093.	1.6	36
180	Infective Endocarditis Following Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007938.	3.9	36

#	ARTICLE	IF	CITATIONS
181	Thrombotic Risk and Antithrombotic Strategies After Transcatheter Mitral Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 2388-2401.	2.9	36
182	Right ventricular systolic function in severe tricuspid regurgitation: prognostic relevance of longitudinal strain. European Heart Journal Cardiovascular Imaging, 2021, 22, 868-875.	1.2	36
183	Prospective Multicenter Evaluation of the Direct Flow Medical Transcatheter Aortic Valve System. JACC: Cardiovascular Interventions, 2016, 9, 68-75.	2.9	35
184	Tricuspid regurgitation: what is the real clinical impact and how often should it be treated?. EuroIntervention, 2018, 14, AB101-AB111.	3.2	35
185	Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. International Journal of Cardiology, 2015, 199, 366-372.	1.7	34
186	Transcatheter Aortic Valve Implantation Under Angiographic Guidance With and Without Adjunctive Transesophageal Echocardiography. American Journal of Cardiology, 2015, 116, 604-611.	1.6	34
187	Impact of Angiographic Result After Predilatation on Outcome After Drug-Coated Balloon Treatment of In-Stent Coronary Restenosis. American Journal of Cardiology, 2016, 118, 1460-1465.	1.6	34
188	Recurrence of Device-Related Thrombus After Percutaneous Left Atrial Appendage Closure. Circulation, 2019, 140, 1441-1443.	1.6	34
189	Clinical and Angiographic Follow-Up of Small Vessel Lesions Treated With Paclitaxel-Eluting Stents (from the TRUE Registry). American Journal of Cardiology, 2008, 102, 1002-1008.	1.6	33
190	Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis. Circulation: Cardiovascular Interventions, 2016, 9, e003148.	3.9	33
191	Persistence of Severe Pulmonary Hypertension After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	33
192	First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 1901-1903.	2.9	33
193	Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. International Journal of Cardiology, 2018, 250, 66-72.	1.7	33
194	Cerebral Protection During Transcatheter Aortic Valve Implantation: An Updated Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2018, 7, .	3.7	33
195	Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis. International Journal of Cardiology, 2014, 173, 513-514.	1.7	32
196	Predictors of restenosis following contemporary subintimal tracking and reentry technique: The importance of final <sc>TIMI</sc> flow grade. Catheterization and Cardiovascular Interventions, 2016, 87, 884-892.	1.7	32
197	Transcatheter Tricuspid Valve-in-Valve and Valve-in-Ring Implantation for Degenerated Surgical Prosthesis. JACC: Cardiovascular Interventions, 2019, 12, 1403-1412.	2.9	32
198	Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads. JACC: Cardiovascular Interventions, 2020, 13, 554-564.	2.9	32

#	ARTICLE	IF	CITATIONS
199	Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. <i>EuroIntervention</i> , 2016, 12, e550-e556.	3.2	32
200	Clinical and anatomical predictors of MitraClip therapy failure for functional mitral regurgitation: single central clip strategy in asymmetric tethering. <i>International Journal of Cardiology</i> , 2015, 186, 286-288.	1.7	31
201	Transcatheter mitral valve regurgitation treatment: State of the art and a glimpse to the future. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 319-327.	0.8	31
202	Impact of anticoagulation therapy on valve haemodynamic deterioration following transcatheter aortic valve replacement. <i>Heart</i> , 2018, 104, 814-820.	2.9	31
203	Transcatheter Tricuspid Valve Replacement: Principles and Design. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 129.	2.4	31
204	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1-month of dual antiplatelet therapy. <i>American Heart Journal</i> , 2019, 214, 134-141.	2.7	31
205	A modified crossover technique for vascular access management in high-risk patients undergoing transfemoral transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 579-583.	1.7	30
206	A comparison of the femoral and radial crossover techniques for vascular access management in transcatheter aortic valve implantation: The milan experience. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 156-161.	1.7	30
207	Transcatheter Tricuspid Valve Repair. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1807-1810.	2.8	30
208	Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 491-498.	3.9	29
209	Comparison of Outcomes of Percutaneous MitraClip Versus Surgical Repair or Replacement for Degenerative Mitral Regurgitation in Octogenarians. <i>American Journal of Cardiology</i> , 2015, 115, 487-492.	1.6	29
210	Incidence, Technical Safety, and Feasibility of Coronary Angiography and Intervention Following Self-expanding Transcatheter Aortic Valve Replacement. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 371-375.	0.8	29
211	Functional and Echocardiographic Improvement After Transcatheter Repair for Tricuspid Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2719-2729.	2.9	29
212	Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 94-100.	1.5	29
213	Clinical Outcomes After Unrestricted Implantation of Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1219-1226.	2.9	28
214	Matched Comparison of Self-Expanding Transcatheter Heart Valves for the Treatment of Failed Aortic Surgical Bioprosthesis. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	28
215	Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 47-56.	1.7	28
216	TAVI with current CE-marked devices: strategies for optimal sizing and valve delivery. <i>EuroIntervention</i> , 2016, 12, Y22-Y27.	3.2	28

#	ARTICLE	IF	CITATIONS
217	Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. International Journal of Cardiology, 2013, 165, 444-447.	1.7	27
218	The Bioresorbable Scaffold. JACC: Cardiovascular Interventions, 2016, 9, 299-300.	2.9	27
219	The Role of Cerebral Embolic Protection Devices During Transcatheter Aortic Valve Replacement. Frontiers in Cardiovascular Medicine, 2018, 5, 150.	2.4	27
220	Complications Following Percutaneous Mitral Valve Repair. Frontiers in Cardiovascular Medicine, 2019, 6, 146.	2.4	27
221	Transfemoral TAVR in Nonagenarians. JACC: Cardiovascular Interventions, 2019, 12, 911-920.	2.9	27
222	Update on Transcatheter Tricuspid Valve Replacement Therapies. Frontiers in Cardiovascular Medicine, 2021, 8, 619558.	2.4	27
223	Post-Implantation Repositioning of the CoreValve Percutaneous Aortic Valve. JACC: Cardiovascular Interventions, 2010, 3, 119-121.	2.9	26
224	Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians (from a Drug-Eluting stent for Left main) Tj ETQq0 0 0 rgBT1/6 Overlock 240 Tf 50 4	2.9	26
225	Safety and feasibility of iliac endovascular interventions with a radial approach. Results from a multicenter study coordinated by the Italian Radial Force. International Journal of Cardiology, 2014, 175, 280-284.	1.7	26
226	Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 2280-2288.	2.9	26
227	Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 2021, 14, e009685.	3.9	26
228	Coronary sinus Reducer non-responders: insights and perspectives. EuroIntervention, 2018, 13, 1667-1669.	3.2	26
229	The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: a comparison with conventional balloon predilatation. EuroIntervention, 2016, 11, e1580-e1588.	3.2	26
230	Two-year outcomes following unprotected left main stenting with first vs. new-generation drug-eluting stents: the FINE registry. EuroIntervention, 2013, 9, 809-816.	3.2	26
231	Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations. American Heart Journal, 2008, 156, 745-750.	2.7	25
232	IVUS-Guided Stent Implantation to Improve Outcome: A Promise Waiting to be Fulfilled. Current Cardiology Reviews, 2009, 5, 78-86.	1.5	25
233	Successful Percutaneous Anterograde Transcatheter Valve-in-Valve Implantation in the Mitral Position. JACC: Cardiovascular Interventions, 2011, 4, 1246-1247.	2.9	25
234	Percutaneous edge-to-edge repair in high-risk and elderly patients with degenerative mitral regurgitation: Midterm outcomes in a single-center experience. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2743-2750.	0.8	25

#	ARTICLE	IF	CITATIONS
235	Clinical outcomes following bioresorbable scaffold implantation for bifurcation lesions: Overall outcomes and comparison between provisional and planned double stenting strategy. Catheterization and Cardiovascular Interventions, 2015, 86, 644-652.	1.7	25
236	Postoperative Delirium in Individuals Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society, 2018, 66, 2417-2424.	2.6	25
237	Clinical outcome and quality of life in octogenarians following transcatheter aortic valve implantation (TAVI) for symptomatic aortic stenosis. International Journal of Cardiology, 2013, 168, 281-286.	1.7	24
238	Impact of Residual Chronic Total Occlusion of Right Coronary Artery on the Long-term Outcome in Patients Treated for Unprotected Left Main Disease. Circulation: Cardiovascular Interventions, 2013, 6, 154-160.	3.9	24
239	Incidence of Bleeding and Compliance on Prolonged Dual Antiplatelet Therapy (Aspirin +) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 1477-1481.	1.6	23
240	1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 440-449.	2.9	23
241	A propensity score matched comparative study between paclitaxel-coated balloon and everolimus-eluting stents for the treatment of small coronary vessels. Catheterization and Cardiovascular Interventions, 2017, 90, 380-386.	1.7	23
242	The coronary sinus reducer: clinical evidence and technical aspects. Expert Review of Cardiovascular Therapy, 2017, 15, 47-58.	1.5	23
243	Orbital atherectomy versus rotational atherectomy: A systematic review and meta-analysis. International Journal of Cardiology, 2020, 303, 16-21.	1.7	23
244	Procedural outcomes of patients with calcified lesions treated with bioresorbable vascular scaffolds. EuroIntervention, 2016, 11, 1355-1362.	3.2	23
245	Defining a new standard for IVUS optimized drug eluting stent implantation: The PRAVIO study. Catheterization and Cardiovascular Interventions, 2009, 74, 348-356.	1.7	22
246	Looking into the future with bioresorbable vascular scaffolds. Expert Review of Cardiovascular Therapy, 2013, 11, 1407-1416.	1.5	22
247	The Long-Term Clinical Outcome of T-Stenting and Small Protrusion Technique for Coronary Bifurcation Lesions. JACC: Cardiovascular Interventions, 2013, 6, 554-561.	2.9	22
248	Procedural Feasibility and Clinical Outcomes in Propensity-Matched Patients Treated With Bioresorbable Scaffolds vs New-Generation Drug-Eluting Stents. Canadian Journal of Cardiology, 2015, 31, 328-334.	1.7	22
249	Safety and efficacy of drug eluting stents in patients with spontaneous coronary artery dissection. International Journal of Cardiology, 2017, 238, 105-109.	1.7	22
250	Impact of Mitral Annular Calcium on Outcomes after Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 2233-2240.	1.6	22
251	A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2017, 10, 1855-1864.	2.9	22
252	Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2017, 69, 378-380.	2.8	22

#	ARTICLE	IF	CITATIONS
253	Patient-Specific Computer Simulation inÂTAVR With the Self-Expanding EvolutÂR Valve. JACC: Cardiovascular Interventions, 2020, 13, 1803-1812.	2.9	22
254	Incidence of Overall Bleeding in Patients Treated With Intra-Aortic Balloon Pump During Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 350-357.	2.9	21
255	First- versus second-generation drug-eluting stents for the treatment of coronary bifurcations. Cardiovascular Revascularization Medicine, 2013, 14, 311-315.	0.8	21
256	Extended followâ€up following â€fullâ€metal jacketâ€percutaneous coronary interventions with drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2014, 84, 1042-1050.	1.7	21
257	A multicenter postâ€marketing evaluation of the Elixir DESolve [®] Novolimusâ€eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. Catheterization and Cardiovascular Interventions, 2018, 92, 1021-1027.	1.7	21
258	Comparison of Transfemoral Versus Transradial Secondary Access in Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e008609.	3.9	21
259	A computed tomography study of coronary access and coronary obstruction after redo transcatheter aortic valve implantation. EuroIntervention, 2020, 16, e1005-e1013.	3.2	21
260	Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates. EuroIntervention, 2012, 8, 429-436.	3.2	21
261	Current and future drug-eluting coronary stent technology. Expert Review of Cardiovascular Therapy, 2011, 9, 485-503.	1.5	20
262	Comparison of First- and Second-Generation Drug-Eluting Stents in Saphenous Vein Grafts Used as Aorto-Coronary Conduits. American Journal of Cardiology, 2013, 112, 318-322.	1.6	20
263	Acute kidney injury following MitraClip implantation in high risk patients: Incidence, predictive factors and prognostic value. International Journal of Cardiology, 2013, 169, e24-e25.	1.7	20
264	Calcification analysis by intravascular ultrasound to define a predictor of left circumflex narrowing after cross-over stenting for unprotected left main bifurcation lesions. Cardiovascular Revascularization Medicine, 2014, 15, 80-85.	0.8	20
265	Usefulness of Baseline Activated Clotting Timeâ€Guided Heparin Administration in Reducing Bleeding Events During Transfemoral Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Interventions, 2014, 7, 140-151.	2.9	20
266	Drugâ€Eluting Balloon in the Treatment of Inâ€Stent Restenosis and Diffuse Coronary Artery Disease: Realâ€World Experience from Our Registry. Journal of Interventional Cardiology, 2014, 27, 348-355.	1.2	20
267	Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	20
268	Long-term results (up to 14 years) of the clover technique for the treatment of complex tricuspid valve regurgitationâ€. European Journal of Cardio-thoracic Surgery, 2017, 52, 125-130.	1.4	20
269	Acute and longâ€term outcomes after polytetrafluoroethylene or pericardium covered stenting for grade 3 coronary artery perforations: Insights from G3â€CAP registry. Catheterization and Cardiovascular Interventions, 2018, 92, 1247-1255.	1.7	20
270	Transcatheter Edge-to-Edge Repair in COAPT-Ineligible Patients: Incidence and Predictors of 2-Year Good Outcome. Canadian Journal of Cardiology, 2022, 38, 320-329.	1.7	20

#	ARTICLE	IF	CITATIONS
271	Surgical Treatment of Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 772-785.	2.8	20
272	Comparison of Long-Term Clinical and Angiographic Outcomes Following Implantation of Bare Metal Stents and Drug-Eluting Stents in Aorto-Ostial Lesions. <i>American Journal of Cardiology</i> , 2011, 108, 1055-1060.	1.6	19
273	The role of intravascular ultrasound and quantitative angiography in the functional assessment of intermediate coronary lesions: Correlation with fractional flow reserve. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 3-7.	0.8	19
274	Impact of gender on long-term mortality in patients with unprotected left main disease: The Milan and New-Tokyo (MITO) Registry. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 369-374.	0.8	19
275	Comparison Between 1- and 2-Stent Strategies in Unprotected Distal Left Main Disease. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	19
276	Minimally invasive or conventional edge-to-edge repair for severe mitral regurgitation due to bileaflet prolapse in Barlow's disease: does the surgical approach have an impact on the long-term results? <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 131-136.	1.4	19
277	In-Hospital and 1-Year Outcomes of Rotational Atherectomy and Stent Implantation in Patients With Severely Calcified Unprotected Left Main Narrowings (from the Multicenter ROTATE Registry). <i>American Journal of Cardiology</i> , 2017, 119, 1331-1337.	1.6	19
278	Percutaneous Tricuspid Valve Annuloplasty Under Conscious Sedation (With Only Fluoroscopic and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.9	19
279	The Impact of Size and Position of a Mechanical Expandable Transcatheter Aortic Valve: Novel Insights Through Computational Modelling and Simulation. <i>Journal of Cardiovascular Translational Research</i> , 2019, 12, 435-446.	2.4	19
280	Machine-Learning-Based In-Hospital Mortality Prediction for Transcatheter Mitral Valve Repair in the United States. <i>Cardiovascular Revascularization Medicine</i> , 2021, 22, 22-28.	0.8	19
281	Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry. <i>International Journal of Cardiology</i> , 2021, 325, 109-114.	1.7	19
282	Temporal Trends, Characteristics, and Outcomes of Infective Endocarditis After Transcatheter Aortic Valve Replacement. <i>Clinical Infectious Diseases</i> , 2021, 73, e3750-e3758.	5.8	19
283	Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2263-2273.	2.8	19
284	When are two stents needed? Which technique is the best? How to perform?. <i>EuroIntervention</i> , 2010, 6, J81-J87.	3.2	19
285	Transseptal access for MitraClip® procedures using surgical diathermy under echocardiographic guidance. <i>EuroIntervention</i> , 2012, 8, 579-586.	3.2	19
286	Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. <i>EuroIntervention</i> , 2016, 11, 989-995.	3.2	19
287	A Comparison Between First-Generation and Second-Generation Transcatheter Aortic Valve Implantation (TAVI) Devices: A Propensity-Matched Single-Center Experience. <i>Journal of Invasive Cardiology</i> , 2016, 28, 210-6.	0.4	19
288	Recognition and management of complications during transcatheter aortic valve implantation. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 913-926.	1.5	18

#	ARTICLE	IF	CITATIONS
289	Transcatheter Aortic Valve Implantation in Patients With Mitral Prosthesis. Journal of the American College of Cardiology, 2012, 60, 1841-1842.	2.8	18
290	Managing Patients With an Indication for Anticoagulant Therapy After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2013, 111, 237-242.	1.6	18
291	Can bioabsorbable scaffolds be used in calcified lesions?. Catheterization and Cardiovascular Interventions, 2014, 84, 48-52.	1.7	18
292	The impact of main branch restenosis on long term mortality following drug-eluting stent implantation in patients with <i>de novo</i> unprotected distal left main bifurcation coronary lesions: The Milan and New Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2014, 84, 341-348.	1.7	18
293	Transcatheter Mitral Valve Replacement in Patients With Previous Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e006412.	3.9	18
294	Emerging Technologies for Percutaneous Mitral Valve Repair. Frontiers in Cardiovascular Medicine, 2019, 6, 161.	2.4	18
295	Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiology, 2020, 5, 92.	6.1	18
296	First-in-Man Study Evaluating the Emblok Embolic Protection System During Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 860-868.	2.9	18
297	Tools and Techniques – Clinical: The inner curve technique for implantation of the Direct Flow Medical® transcatheter aortic valve. EuroIntervention, 2014, 10, 400-402.	3.2	18
298	Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization. Nature Reviews Cardiology, 2023, 20, 52-67.	13.7	18
299	Coronary Left Main and Non-Left Main Bifurcation Angles: How are the Angles Modified by Different Bifurcation Stenting Techniques?. Journal of Interventional Cardiology, 2010, 23, 382-393.	1.2	17
300	Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts. Circulation: Cardiovascular Interventions, 2010, 3, 249-256.	3.9	17
301	Left Bundle Branch Block After Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2012, 60, 1753-1755.	2.8	17
302	Procedural trauma risks longitudinal shortening of the promus element, stent platform. Catheterization and Cardiovascular Interventions, 2013, 81, 810-817.	1.7	17
303	Feasibility of ultra-low contrast 64-slice computed tomography angiography before transcatheter aortic valve implantation: a real-world experience. European Heart Journal Cardiovascular Imaging, 2015, 17, 175.	1.2	17
304	Coronary Bioresorbable Vascular Scaffold Use in the Treatment of Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	17
305	Long-term follow-up of covered stent implantation for various coronary artery diseases. Catheterization and Cardiovascular Interventions, 2019, 94, 571-577.	1.7	17
306	Lessons from the GHOST-EU registry. EuroIntervention, 2015, 11, V170-V174.	3.2	17

#	ARTICLE	IF	CITATIONS
307	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. <i>EuroIntervention</i> , 2016, 12, e623-e631.	3.2	17
308	Long-term clinical outcomes following drug-eluting stent implantation for unprotected distal trifurcation left main disease: The Milan-New Tokyo (MITO) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 530-538.	1.7	16
309	Bioresorbable Scaffolds for the Management of Coronary Bifurcation Lesions. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 989-1000.	2.9	16
310	Long-Term Outcomes After Transcatheter Aortic Valve Implantation from a Single High-Volume Center (The Milan Experience). <i>American Journal of Cardiology</i> , 2016, 117, 813-819.	1.6	16
311	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 560-568.	2.9	16
312	Post-infarct ventricular septal rupture: early Impella implantation to delay surgery and reduce surgical risk. <i>Cardiovascular Intervention and Therapeutics</i> , 2017, 32, 381-385.	2.3	16
313	Accuracy and reproducibility of aortic annular measurements obtained from echocardiographic 3D manual and semi-automated software analyses in patients referred for transcatheter aortic valve implantation: implication for prosthesis size selection. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 45-55.	1.2	16
314	Use of edge-to-edge percutaneous mitral valve repair for severe mitral regurgitation in cardiogenic shock: A multicenter observational experience (MITRA-CHOCK study). <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E163-E170.	1.7	16
315	The failing right heart: implications and evolution in high-risk patients undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2016, 12, 1542-1549.	3.2	16
316	Impact of horizontal aorta on procedural and clinical outcomes in second-generation transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2019, 15, e749-e756.	3.2	16
317	Treatment of iatrogenic occlusive coronary dissections: a novel approach. <i>EuroIntervention</i> , 2011, 7, 106-111.	3.2	16
318	Outcomes of valve-in-valve transcatheter aortic valve implantation with and without bioprosthetic valve fracture. <i>EuroIntervention</i> , 2021, 17, 848-855.	3.2	16
319	Protamine usage following implantation of drug-eluting stents: A word of caution. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 913-914.	1.7	15
320	Transaxillary Approach Short- and Mid-Term Results in a Single-Center Experience. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2011, 6, 361-365.	0.9	15
321	Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 522-528.	1.7	15
322	Use of Echocardiography for Guiding Percutaneous Tricuspid Valve Procedures. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1194-1198.	5.3	15
323	Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 812-818.	1.7	15
324	Transradial versus transfemoral ancillary approach in complex structural, coronary, and peripheral interventions. Results from the multicenter ancillary registry: A study of the Italian Radial Club. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 97-102.	1.7	15

#	ARTICLE	IF	CITATIONS
325	Impact of Predilatation Prior to Transcatheter Aortic Valve Implantation With the Self-Expanding Acurate neo Device (from the Multicenter NEOPRO Registry). American Journal of Cardiology, 2020, 125, 1369-1377.	1.6	15
326	Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions. EuroIntervention, 2017, 13, 355-363.	3.2	15
327	Percutaneous valve replacement in a young adult for radiation-induced aortic stenosis. Journal of Cardiovascular Medicine, 2012, 13, 397-398.	1.5	14
328	Impact of Mean Platelet Volume on Combined Safety Endpoint and Vascular and Bleeding Complications following Percutaneous Transfemoral Transcatheter Aortic Valve Implantation. BioMed Research International, 2013, 2013, 1-8.	1.9	14
329	Differences in the Clinical and Angiographic Characteristics of Chronic Total Occlusion Lesions in the Three Major Coronary Arteries. Journal of Interventional Cardiology, 2014, 27, 44-49.	1.2	14
330	Transfemoral transcatheter aortic valve implantation in patients with small diseased peripheral vessels. Cardiovascular Revascularization Medicine, 2015, 16, 326-330.	0.8	14
331	Is Transcatheter Aortic Valve Replacement Superior to Surgical Aortic Valve Replacement?. JACC: Cardiovascular Interventions, 2017, 10, 1899-1901.	2.9	14
332	Mid-term clinical outcomes after bailout drug-eluting stenting for suboptimal drug-coated balloon results: Insights from a Milan registry. International Journal of Cardiology, 2018, 263, 17-23.	1.7	14
333	Percutaneous Direct Annuloplasty With Edge-to-Edge Technique for Mitral Regurgitation: Replicating a Complete Surgical Mitral Repair in a One-Step Procedure. Canadian Journal of Cardiology, 2018, 34, 1088.e1-1088.e2.	1.7	14
334	Transcatheter Aortic Valve Implantation (TAVI) for Native Aortic Valve Regurgitation—A Systematic Review. Circulation Journal, 2018, 82, 895-902.	1.6	14
335	Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 20-27.	3.0	14
336	Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry). EuroIntervention, 2010, 5, 906-916.	3.2	14
337	Self-Expanding Prostheses for Transcatheter Aortic Valve Replacement. Progress in Cardiovascular Diseases, 2014, 56, 596-609.	3.1	13
338	Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents. Catheterization and Cardiovascular Interventions, 2015, 86, 1168-1176.	1.7	13
339	Valve embolization with a second-generation fully-retrievable and repositionable transcatheter aortic valve. International Journal of Cardiology, 2016, 223, 867-869.	1.7	13
340	Percutaneous Transcatheter Treatment for Tricuspid Bioprosthesis Failure. Catheterization and Cardiovascular Interventions, 2016, 88, 994-1001.	1.7	13
341	The ratio of contrast volume to glomerular filtration rate predicts acute kidney injury and mortality after transcatheter aortic valve implantation. Cardiovascular Revascularization Medicine, 2017, 18, 349-355.	0.8	13
342	Unprotected left main revascularization: Percutaneous coronary intervention versus coronary artery bypass. An updated systematic review and meta-analysis of randomised controlled trials. PLoS ONE, 2017, 12, e0179060.	2.5	13

#	ARTICLE	IF	CITATIONS
343	Cerebral Embolic Risk During Transcatheter Mitral Valve Interventions. JACC: Cardiovascular Interventions, 2018, 11, 517-528.	2.9	13
344	Delayed Coronary Occlusion After Transcatheter Aortic Valve Implantation: Implications for New Transcatheter Heart Valve Design and Patient Management. Interventional Cardiology Review, 2018, 13, 137.	1.6	13
345	Current Generation Balloon-Expandable Transcatheter Valve Positioning Strategies During Aortic Valve-in-Valve Procedures and Clinical Outcomes. JACC: Cardiovascular Interventions, 2019, 12, 1606-1617.	2.9	13
346	Feasibility, Safety, and Efficacy of Intravascular Lithotripsy in Severely Calcified Left Main Coronary Stenosis. JACC: Cardiovascular Interventions, 2020, 13, 1727-1729.	2.9	13
347	Incidence, predictors and outcomes of valve-in-valve TAVI: A systematic review and meta-analysis. International Journal of Cardiology, 2020, 316, 64-69.	1.7	13
348	Patient selection, procedural planning and interventional guidance for transcatheter aortic valve intervention. Minerva Cardiology and Angiology, 2021, 69, 671-683.	0.7	13
349	Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves: The TRANSIT International Project. Circulation: Cardiovascular Interventions, 2021, 14, e010440.	3.9	13
350	A novel supra-annular plane to predict TAVI prosthesis anchoring in raphe-type bicuspid aortic valve disease: the LIRA plane. EuroIntervention, 2020, 16, 259-261.	3.2	13
351	Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the "no more metallic cages" multicentre pilot experience. EuroIntervention, 2016, 11, e1589-e1595.	3.2	13
352	First-in-man transcatheter mitral valve-in-ring implantation with a repositionable and retrievable aortic valve prosthesis. EuroIntervention, 2016, 11, 1148-1152.	3.2	13
353	Long-Term Outcomes After Infective Endocarditis After Transcatheter Aortic Valve Replacement. Circulation, 2020, 142, 1497-1499.	1.6	13
354	Use of BVS in a chronic total occlusion with bifurcation lesion. International Journal of Cardiology, 2013, 167, e129-e131.	1.7	12
355	Single-stent crossover technique from distal unprotected left main coronary artery to the left circumflex artery. Catheterization and Cardiovascular Interventions, 2013, 82, 757-764.	1.7	12
356	A Case of True Left Main Bifurcation Treated With Bioresorbable Everolimus-Eluting Stent V-Stenting. JACC: Cardiovascular Interventions, 2014, 7, e103-e104.	2.9	12
357	Transcatheter aortic valve implantation of the direct flow medical aortic valve with minimal or no contrast. Cardiovascular Revascularization Medicine, 2014, 15, 252-257.	0.8	12
358	Red blood cell distribution width predicts one-year mortality following transcatheter aortic valve implantation. International Journal of Cardiology, 2014, 172, 456-457.	1.7	12
359	Influence of baseline ejection fraction on the prognostic value of paravalvular leak after transcatheter aortic valve implantation. International Journal of Cardiology, 2015, 190, 277-281.	1.7	12
360	Impact of post-procedural hyperglycemia on acute kidney injury after transcatheter aortic valve implantation. International Journal of Cardiology, 2016, 221, 892-897.	1.7	12

#	ARTICLE	IF	CITATIONS
361	Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients â€” results from the BELLO (balloon elution and late loss) Tj ETQq1 1 0.784314.8 BT / Overlock 10.7	1.6	12
362	Analysis of a Low Dose Protocol to Reduce Patient Radiation Exposure During Percutaneous Coronary Interventions. American Journal of Cardiology, 2017, 119, 203-209.	1.6	12
363	Percutaneous Tricuspid Annuloplasty. Interventional Cardiology Clinics, 2018, 7, 31-36.	0.4	12
364	Transcatheter Aortic Valve Replacement Outcomes in Patients With Native vs Transplanted Kidneys: Data From an International Multicenter Registry. Canadian Journal of Cardiology, 2019, 35, 1114-1123.	1.7	12
365	Stroke Complicating Infective Endocarditis After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2276-2287.	2.8	12
366	Predilatation Prior to Transcatheter Aortic Valve Implantation: Is it Still a Prerequisite?. Interventional Cardiology Review, 2017, 12, 116.	1.6	12
367	Leaflet edge-to-edge treatment versus direct annuloplasty in patients with functional mitral regurgitation. EuroIntervention, 2019, 15, 912-918.	3.2	12
368	The Cappella Sideguardâ„¢ stent. EuroIntervention, 2010, 6, J143-J146.	3.2	12
369	An Update on New Generation Transcatheter Aortic Valves and Delivery Systems. Journal of Clinical Medicine, 2022, 11, 499.	2.4	12
370	A high dose of adenosine to induce transient asystole for valvuloplasty in patients undergoing transcatheter aortic valve implantation (TAVI): is it a valid alternative to rapid pacing? A prospective pilot study. Journal of Invasive Cardiology, 2011, 23, 467-71.	0.4	12
371	Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type. JACC: Cardiovascular Interventions, 2022, 15, 1543-1554.	2.9	12
372	Late incomplete stent apposition after drug-eluting stent implantation: a true risk factor or "an innocent bystander"? Heart, 2008, 94, 253-254.	2.9	11
373	Optical Coherence Tomography of a Bifurcation Lesion Treated With Bioresorbable Vascular Scaffolds With the â€œMini-Crushâ€”Technique. JACC: Cardiovascular Interventions, 2013, 6, 1326-1327.	2.9	11
374	Association of baseline C-reactive protein levels with periprocedural myocardial injury in patients undergoing percutaneous bifurcation intervention: A CACTUS study subanalysis. Catheterization and Cardiovascular Interventions, 2014, 83, E37-44.	1.7	11
375	Bicuspid Aortic Valve. Journal of the American College of Cardiology, 2014, 64, 2340-2342.	2.8	11
376	Acute and long-term (2-years) clinical outcomes of the CoreValve 31 mm in large aortic annuli: A multicenter study. International Journal of Cardiology, 2017, 227, 543-549.	1.7	11
377	Percutaneous bicuspidalization of the tricuspid valve using the MitraClip system. International Journal of Cardiovascular Imaging, 2017, 33, 227-228.	1.5	11
378	Long-term outcomes following miniâ€”crush versus culotte stenting for the treatment of unprotected left main disease: Insights from the milan and Newâ€”Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2017, 89, 13-24.	1.7	11

#	ARTICLE	IF	CITATIONS
379	Echocardiographic features of post-transcatheter aortic valve implantation thrombosis and endocarditis. <i>Echocardiography</i> , 2018, 35, 337-345.	0.9	11
380	Transcatheter Valve Replacement in Asia-Pacific. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3189-3199.	2.8	11
381	Current results and remaining challenges of trans-catheter aortic valve replacement expansion in intermediate and low risk patients. <i>IJC Heart and Vasculature</i> , 2019, 23, 100375.	1.1	11
382	Future Perspectives in Percutaneous Treatment of Tricuspid Regurgitation. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 581211.	2.4	11
383	Transcatheter tricuspid valve implantation with the Cardiovalve system. <i>Future Cardiology</i> , 2021, 17, 963-969.	1.2	11
384	Percutaneous repair of the tricuspid valve using a novel cinching device: acute and chronic experience in a preclinical large animal model. <i>EuroIntervention</i> , 2016, 12, 918-925.	3.2	11
385	Meta-Analysis Comparing Outcomes With Bifurcation Percutaneous Coronary Intervention Techniques. <i>American Journal of Cardiology</i> , 2022, 165, 37-45.	1.6	11
386	Outcomes in Valve-in-Valve Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2022, 172, 81-89.	1.6	11
387	Perivalvular Extension of Infective Endocarditis After Transcatheter Aortic Valve Replacement. <i>Clinical Infectious Diseases</i> , 2022, 75, 638-646.	5.8	11
388	10-Year Impact of Transcatheter Aortic Valve Replacement Leaflet Design (Intra- Versus Supra-Annular) in Mortality and Hemodynamic Performance. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	11
389	Long-term follow-up of multivessel percutaneous coronary intervention with drug-eluting stents for de novo lesions with correlation to the SYNTAX score. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 220-227.	0.8	10
390	A Novel Device for True Lumen Re-Entry After Subintimal Recanalization of Superficial Femoral Arteries: First-in-Man Experience and Technical Description. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 166-169.	2.0	10
391	Resultados a muy largo plazo tras la implantación de stents liberadores de fármacos en la estenosis de arteria coronaria principal izquierda no protegida: experiencia de un centro. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 24-33.	1.2	10
392	Current and new-generation transcatheter aortic valve devices: an update on emerging technologies. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1393-1405.	1.5	10
393	Bioresorbable vascular scaffolds for left main lesions; a novel strategy to overcome limitations. <i>International Journal of Cardiology</i> , 2014, 175, e11-e13.	1.7	10
394	Transcatheter aortic valve implantation in patients with severe aortic valve stenosis and large aortic annulus, using the self-expanding 31-mm Medtronic CoreValve prosthesis: First clinical experience. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 492-499.e1.	0.8	10
395	Optimal Duration of Dual Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: Lessons From Optical Coherence Tomography. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1460.e15-1460.e17.	1.7	10
396	Feasibility and Efficacy of Bioresorbable Vascular Scaffolds Use for the Treatment of In-Stent Restenosis and a Bifurcation Lesion in Heavily Calcified Diffusely Diseased Vessel. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, e45-e46.	2.9	10

#	ARTICLE	IF	CITATIONS
397	Early Outcomes With Direct Flow Medical Versus First-Generation Transcatheter Aortic Valve Devices: A Single-Center Propensity-Matched Analysis. <i>Journal of Interventional Cardiology</i> , 2015, 28, 583-593.	1.2	10
398	Hybrid Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffolds in Combination With Drug-Eluting Stents or Drug-Coated Balloons for Complex Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 539-547.	2.9	10
399	Comparison of mid-term clinical outcomes after treatment of ostial right coronary artery lesions with early and new generation drug-eluting stents: Insights from an international multicenter registry. <i>International Journal of Cardiology</i> , 2018, 254, 53-58.	1.7	10
400	Current Devices and Complications Related to Transcatheter Mitral Valve Replacement: The Bumpy Road to the Top. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 639058.	2.4	10
401	Is it time to simplify the TAVI procedure? "Make it simple but not too simple". <i>EuroIntervention</i> , 2014, 10, U22-U27.	3.2	10
402	Trends in Transcatheter vs Surgical Mitral Valve Repair Among Medicare Beneficiaries, 2012 to 2019. <i>JAMA Cardiology</i> , 2022, 7, 770.	6.1	10
403	Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1153-1163.	2.9	10
404	Clinical Outcomes Following Protected Carotid Artery Stenting in Symptomatic and Asymptomatic Patients. <i>Journal of Endovascular Therapy</i> , 2010, 17, 298-307.	1.5	9
405	Discrepancies in vessel sizing between angiography and intravascular ultrasound varies according to the vessel evaluated. <i>International Journal of Cardiology</i> , 2013, 168, 3791-3796.	1.7	9
406	Late Downward Dislocation of a Balloon Expandable Valve Into the Left Ventricular Outflow Tract Following Transfemoral Transcatheter Aortic Valve Implantation. <i>Circulation Journal</i> , 2013, 77, 1345-1347.	1.6	9
407	No more metallic cages: An attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel. <i>International Journal of Cardiology</i> , 2014, 172, 618-619.	1.7	9
408	Short-term outcomes following "full-plastic jacket" everolimus-eluting bioresorbable scaffold implantation. <i>International Journal of Cardiology</i> , 2014, 177, 607-609.	1.7	9
409	Acute stent thrombosis of a bioresorbable vascular scaffold implanted for ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 174, e72-e74.	1.7	9
410	A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY study. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1129-1138.	1.7	9
411	Subclinical Leaflet Thrombosis and Clinical Outcomes after TAVR: A Systematic Review and Meta-Analysis. <i>Structural Heart</i> , 2018, 2, 223-228.	0.6	9
412	Percutaneous mechanical circulatory support from the collaborative multicenter Mechanical Unusual Support in TAVI (MUST) Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E862-E869.	1.7	9
413	A multicentre European registry to evaluate the Direct Flow Medical transcatheter aortic valve system for the treatment of patients with severe aortic stenosis. <i>EuroIntervention</i> , 2016, 12, e1413-e1419.	3.2	9
414	Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry. <i>EuroIntervention</i> , 2017, 13, e1104-e1111.	3.2	9

#	ARTICLE	IF	CITATIONS
415	Very Late Restenosis after Paclitaxel-Eluting Stent Implantation. <i>Annals of Internal Medicine</i> , 2007, 147, 885.	3.9	9
416	Infective Endocarditis Caused by <i>Staphylococcus aureus</i> After Transcatheter Aortic Valve Replacement. <i>Canadian Journal of Cardiology</i> , 2022, 38, 102-112.	1.7	9
417	Emerging Transcatheter Options for Tricuspid Regurgitation. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 13, 120.	1.0	9
418	Diagnostic performance and prognostic impact of coronary angiography-based Index of Microcirculatory Resistance assessment: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 286-292.	1.7	9
419	Impact of inferior vena cava entry characteristics on tricuspid annular access during transcatheter interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1268-1276.	1.7	9
420	Transcatheter mitral repair and replacement: state of the art and future directions. <i>Journal of Heart Valve Disease</i> , 2014, 23, 492-505.	0.5	9
421	Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results. <i>Journal of Invasive Cardiology</i> , 2015, 27, 461-6.	0.4	9
422	Can Long-Term Results Following Balloon Angioplasty Be the "Crystal Ball" to Predict Outcome Following Bioresorbable Vascular Scaffolds?. <i>Journal of the American Heart Association</i> , 2012, 1, e005272.	3.7	8
423	Assessment of Efficacy and Safety of Combining "Paclitaxel-Eluting Balloon and "Limus-Eluting Stent in the Same Lesion. <i>Journal of Interventional Cardiology</i> , 2013, 26, 259-263.	1.2	8
424	Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 889-895.	1.7	8
425	First generation versus new generation drug-eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: The Milan and New-Tokyo (MITO) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, E63-9.	1.7	8
426	First-in-Human Implantation of a Direct Flow Medical Valve in a Radiolucent Mitral Annuloplasty Ring. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, e105-e108.	2.9	8
427	Recent advances in transcatheter aortic valve replacement for high-risk patients. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1237-1249.	1.5	8
428	Clinical outcomes following bifurcation double-stenting with bioresorbable scaffolds. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 854-862.	1.7	8
429	TCT-86 Early Experience with the Trialalign System for Transcatheter Tricuspid Valve Repair: A Multicenter Experience. <i>Journal of the American College of Cardiology</i> , 2016, 68, B35.	2.8	8
430	Bioresorbable vascular scaffolds: From patient selection to optimal scaffold implantation; tips and tricks to minimize device failure. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 10-20.	1.7	8
431	Clinical Outcomes After Implantation of Overlapping Bioresorbable Scaffolds vs New Generation Everolimus Eluting Stents. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 1135-1143.	0.6	8
432	First in man prolonged pressure-controlled intermittent coronary sinus occlusion to treat refractory left ventricular dysfunction and ischemia with patent epicardial coronary arteries. <i>International Journal of Cardiology</i> , 2017, 241, 138-141.	1.7	8

#	ARTICLE	IF	CITATIONS
433	Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the <scp>E</scp>uropean <scp>M</scp>ulticentre <scp>GHOST</scp>â€<scp>EU</scp><scp>R</scp>egistry. Catheterization and Cardiovascular Interventions, 2018, 91, 444-453.	1.7	8
434	Comparison of Early and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients with New York Heart Association Functional Class IV to those in Class III and Less. American Journal of Cardiology, 2018, 122, 1718-1726.	1.6	8
435	Long-term follow-up of BVS from a prospective multicenter registry: Impact of a dedicated implantation technique on clinical outcomes. International Journal of Cardiology, 2018, 270, 113-117.	1.7	8
436	Chimney technique for coronary obstruction after aortic valve in valve: pros and cons. European Heart Journal Cardiovascular Imaging, 2018, 19, 1194-1194.	1.2	8
437	Buddyâ€wire technique during rotational Atherectomy: Simple and effective solution to achieve strong backâ€up support. Catheterization and Cardiovascular Interventions, 2019, 93, 436-439.	1.7	8
438	Anatomic and procedural associations of transcatheter heart valve displacement following Evolut R implantation. Catheterization and Cardiovascular Interventions, 2019, 93, 522-529.	1.7	8
439	Interaction between severe chronic kidney disease and acute kidney injury in predicting mortality after transcatheter aortic valve implantation: Insights from the Italian Clinical Service Project. Catheterization and Cardiovascular Interventions, 2020, 96, 1500-1508.	1.7	8
440	Predictors of high residual gradient after transcatheter aortic valve replacement in bicuspid aortic valve stenosis. Clinical Research in Cardiology, 2021, 110, 667-675.	3.3	8
441	Incidence, Management, Immediate and Long-Term Outcome of Guidewire and Device Related Grade III Coronary Perforations (from G3CAP - Cardiogroup VI Registry). American Journal of Cardiology, 2021, 143, 37-45.	1.6	8
442	MitraClip After Failed Surgical Mitral Valve Repairâ€”An International Multicenter Study. Journal of the American Heart Association, 2021, 10, e019236.	3.7	8
443	Coronary physiologic assessment based on angiography and intracoronary imaging. Journal of Cardiology, 2022, 79, 71-78.	1.9	8
444	Meta-Analysis Comparing Valve Durability Among Different Transcatheter and Surgical Aortic Valve Bioprosthesis. American Journal of Cardiology, 2021, 158, 104-111.	1.6	8
445	First-in-human evaluation of a novel sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold: 9- and 24-month imaging and clinical results of the RENASCENT II trial. EuroIntervention, 2020, 16, e133-e140.	3.2	8
446	Preliminary outcomes after transcatheter aortic valve implantation in patients with systemic sclerosis. EuroIntervention, 2015, 10, 1464-1467.	3.2	8
447	Transcatheter Coronary Sinus Interventions. JACC: Cardiovascular Interventions, 2022, 15, 1397-1412.	2.9	8
448	Surgeons and Interventional Cardiologists in a Collaborative Environmentâ€Žâ€ŽEditorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology, 2009, 53, 242-243.	2.8	7
449	Drug-coated balloons in interventional cardiology. Expert Review of Cardiovascular Therapy, 2013, 11, 1379-1391.	1.5	7
450	Bioresorbable vascular scaffold strut disruption after crossing with an optical coherence tomography imaging catheter. International Journal of Cardiology, 2014, 174, e116-e119.	1.7	7

#	ARTICLE	IF	CITATIONS
451	Side Branch Occlusion After Bioresorbable Vascular Scaffold Implantation. JACC: Cardiovascular Interventions, 2015, 8, 116-118.	2.9	7
452	Echocardiographic vs Invasive Measurement of the Direct Flow Transcatheter Aortic Heart Valve Mean Gradient: Contradictory or Complementary?. Canadian Journal of Cardiology, 2015, 31, 1303.e1-1303.e4.	1.7	7
453	Positive Vessel Remodeling and Appearance of Pulsatile Wall Motion at Long-Term Follow-Up After Bioresorbable Scaffold Implantation in a Chronic Total Occlusion. JACC: Cardiovascular Interventions, 2015, 8, 1635-1637.	2.9	7
454	Transcatheter aortic valve implantation in intermediate- and low-risk populations: An inevitable progression?. International Journal of Cardiology, 2016, 210, 35-37.	1.7	7
455	Percutaneous Mitral Annuloplasty. Interventional Cardiology Clinics, 2016, 5, 101-107.	0.4	7
456	Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions. International Journal of Cardiology, 2017, 246, 26-31.	1.7	7
457	The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure. Netherlands Heart Journal, 2017, 25, 536-544.	0.8	7
458	Percutaneous left atrial appendage occlusion with the Amulet device: The impact of device disc position upon periprocedural and long-term outcomes. Catheterization and Cardiovascular Interventions, 2019, 93, 120-127.	1.7	7
459	Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis. Catheterization and Cardiovascular Interventions, 2021, 97, 581-588.	1.7	7
460	Transcatheter Mitral Valve Replacement: Current Evidence and Concepts. Interventional Cardiology Review, 2021, 16, e07.	1.6	7
461	Contemporary technologies to modify calcified plaque in coronary artery disease. Progress in Cardiovascular Diseases, 2021, 69, 18-26.	3.1	7
462	Balloon-Expandable versus Self-Expandable Valves in Transcatheter Aortic Valve Implantation: Complications and Outcomes from a Large International Patient Cohort. Journal of Clinical Medicine, 2021, 10, 4005.	2.4	7
463	Assessing the Risk of Leaflet Motion Abnormality Following Transcatheter Aortic Valve Implantation. Interventional Cardiology Review, 2017, 13, 1.	1.6	7
464	Transfemoral transcatheter aortic valve replacement without contrast medium using the Medtronic CoreValve system: a single center experience. Journal of Cardiovascular Surgery, 2020, 61, 489-495.	0.6	7
465	Real-world multicentre experience with the Direct Flow Medical® repositionable and retrievable transcatheter aortic valve implantation system for the treatment of high-risk patients with severe aortic stenosis. EuroIntervention, 2016, 11, e1314-e1320.	3.2	7
466	Coronary bifurcations as you have never seen them: the Visible Heart® Laboratory bifurcation programme. EuroIntervention, 2015, 11, V40-V43.	3.2	7
467	Platelets. JACC Basic To Translational Science, 2021, 6, 1007-1020.	4.1	7
468	New-generation drug-eluting stent experience in the percutaneous treatment of unprotected left main coronary artery disease: the NEST registry. Journal of Invasive Cardiology, 2013, 25, 269-75.	0.4	7

#	ARTICLE	IF	CITATIONS
469	Management and Outcome of Failed Percutaneous Edge-to-Edge Mitral Valve Plication. JACC: Cardiovascular Interventions, 2022, 15, 411-422.	2.9	7
470	Prolonged Double Antiplatelet Therapy in a Cohort of De Novo Diabetic Patients Treated With Drug-Eluting Stent Implantation. American Journal of Cardiology, 2010, 105, 1395-1401.	1.6	6
471	Tardive Coronary Obstruction By a Native Leaflet After Transcatheter Aortic Valve Replacement in a Patient With Heavily Calcified Aortic Valve Stenosis. JACC: Cardiovascular Interventions, 2014, 7, e105-e107.	2.9	6
472	Impact of renal dysfunction on long-term mortality in patients with unprotected left main disease: Milan and New-Tokyo (MITO) Registry. International Journal of Cardiology, 2014, 177, 1131-1133.	1.7	6
473	Bioresorbable scaffolds for treatment of coronary bifurcation lesions: Critical appraisal and future perspectives. Catheterization and Cardiovascular Interventions, 2016, 88, 397-406.	1.7	6
474	Clinical outcomes following target lesion revascularization for bioresorbable scaffold failure. Catheterization and Cardiovascular Interventions, 2016, 87, 832-836.	1.7	6
475	Sustained Reduction of Tricuspid Regurgitation After Percutaneous Repair With the MitraClip System in a Patient With a Dual Chamber Pacemaker. JACC: Cardiovascular Interventions, 2017, 10, e147-e149.	2.9	6
476	Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study). Catheterization and Cardiovascular Interventions, 2018, 92, 668-677.	1.7	6
477	Trends in Utilization of Surgical and Transcatheter Mitral Valve Repair in the United States†. American Journal of Cardiology, 2019, 123, 1187-1189.	1.6	6
478	Transcatheter Mitral Valve Implantation: Who are we Treating and What may we Expect?. American Journal of Cardiology, 2019, 123, 1884-1885.	1.6	6
479	One-Year Results Following a Pre-Specified ABSORB Implantation Strategy in ST-Elevation Myocardial Infarction (BVS STEMI STRATEGY-IT Study). Cardiovascular Revascularization Medicine, 2019, 20, 700-704.	0.8	6
480	Aortic valve area calculation using 3D transesophageal echocardiography: Implications for aortic stenosis severity grading. Echocardiography, 2020, 37, 2071-2081.	0.9	6
481	Outcome of Coronary Ostial Stenting to Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e009017.	3.9	6
482	Italian Multicenter Registry of Bare Metal Stent Use in Modern Percutaneous Coronary Intervention Era (AMARCORD): A multicenter observational study. Catheterization and Cardiovascular Interventions, 2021, 97, 411-420.	1.7	6
483	Transcatheter tricuspid valve repair and replacement: a landscape review of current techniques and devices for the treatment of tricuspid valve regurgitation. Expert Review of Cardiovascular Therapy, 2021, 19, 399-411.	1.5	6
484	Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study. Catheterization and Cardiovascular Interventions, 2021, 98, 756-764.	1.7	6
485	Transfemoral Transcatheter Tricuspid Valve Replacement. JACC: Cardiovascular Interventions, 2022, 15, 492-495.	2.9	6
486	Diagnostic performance of fractional flow reserve derived from coronary angiography, intravascular ultrasound, and optical coherence tomography; a meta-analysis. Journal of Cardiology, 2022, 80, 1-8.	1.9	6

#	ARTICLE	IF	CITATIONS
487	Very early infective endocarditis after transcatheter aortic valve replacement. <i>Clinical Research in Cardiology</i> , 2022, 111, 1087-1097.	3.3	6
488	Clinical significance of myocardial work parameters after acute myocardial infarction. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	6
489	Percutaneous treatment of a popliteal bifurcationâ€”The value of coronary devices and strategies. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 710-713.	1.7	5
490	Broken heart syndrome: tako-tsubo cardiomyopathy. <i>Cmaj</i> , 2009, 180, 1033-1034.	2.0	5
491	One-Year Follow-Up Optical Coherence Tomography After Implantation of Bioresorbable Vascular Scaffolds for aâ€”Chronic Coronary Total Occlusion. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, e157-e159.	2.9	5
492	Long term follow-up of â€œfull metal jacketâ€”of de novo coronary lesions with new generation Zotarolimus-eluting stents. <i>International Journal of Cardiology</i> , 2016, 221, 1008-1012.	1.7	5
493	Preliminary Report of Clinical Outcomes After Single Crossover Bioresorbable Scaffold Implantation Without Routine Side Branch Strut Dilation. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 865-870.	1.7	5
494	Contained coronary rupture following bioresorbable scaffold implantation in a small vessel. <i>International Journal of Cardiology</i> , 2016, 209, 24-25.	1.7	5
495	Percutaneous Bicuspidization of the Tricuspidâ€”Valve. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 488-489.	5.3	5
496	Mitral Valve-in-Ring Implantation With a Dedicated Transcatheter Mitral Valve Replacement System. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1012-1014.	2.9	5
497	Transfemoral Implantation of a Balloon-Expandable Transcatheter Valveâ€”in a Rigid Mitral Annuloplasty Ringâ€”Optimized by Post-Dilatation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, e177-e179.	2.9	5
498	Five-year evolution of mild aortic regurgitation following transcatheter aortic valve implantation: early insights from a single-centre experience. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 25, 75-82.	1.1	5
499	Anesthetic Management of Cardioband Implantation: Data From a Preliminary Experience and New Insights. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 482-488.	1.3	5
500	Expansion in calcific lesions and overall clinical outcomes following bioresorbable scaffold implantation optimized with intravascular ultrasound. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 789-797.	1.7	5
501	Tearing Down the Risk for Coronaryâ€”Obstruction With Transcatheterâ€”Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 690-692.	2.9	5
502	Repeat MitraClip for early recurrent mitral regurgitation. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 611-616.	1.7	5
503	Usefulness of Buddy Wire Technique During Transcatheter Transseptal Mitral Valve Implantation in Degenerated Mitral Bioprosthesis. <i>Circulation Journal</i> , 2018, 83, 243-244.	1.6	5
504	Transcatheter Interventions for Severe TR Patients Presenting to a Tertiary Care Setting. <i>Journal of the American College of Cardiology</i> , 2019, 74, 821-823.	2.8	5

#	ARTICLE	IF	CITATIONS
505	Thrombotic Complications and Cerebrovascular Events in Takotsubo Syndrome: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2019, 35, 230.e9-230.e10.	1.7	5
506	Magmaris Bioresorbable Scaffold â€• Possible Dismantling 2 Months After Implantation on Intravascular Ultrasound â€•. Circulation Journal, 2019, 83, 1418.	1.6	5
507	Severe Valvular Heart Disease and COVID-19: Results from the Multicenter International Valve Disease Registry. Structural Heart, 2021, 5, 424-426.	0.6	5
508	Systematic Fluoroscopic-Echocardiographic Fusion Imaging Protocol for Transcatheter Edge-to-Edge Mitral Valve Repair Intraprocedural Monitoring. Journal of the American Society of Echocardiography, 2021, 34, 604-613.	2.8	5
509	A Practical Approach to Assessing Stent Results with IVUS or OCT. Methodist DeBakey Cardiovascular Journal, 2021, 14, 32.	1.0	5
510	The five Ws of transcatheter tricuspid valve repair: Who, What, When, Where, and Why. EuroIntervention, 2019, 15, 841-845.	3.2	5
511	A Glimpse Into the Future of Transcatheter Interventional Heart Failure Therapies. JACC Basic To Translational Science, 2021, 7, 181-191.	4.1	5
512	The role of everolimus-eluting and resolute zotarolimus-eluting stents in the treatment of coronary bifurcations. Journal of Invasive Cardiology, 2013, 25, 436-40.	0.4	5
513	Bioresorbable Vascular Scaffolds for Heavily Calcified Lesions: How to Tackle the Rugged Passage?. Journal of Invasive Cardiology, 2015, 27, E167-8.	0.4	5
514	Drug elution without the need for stent struts and polymers: a promising technology?. Interventional Cardiology, 2012, 4, 291-295.	0.0	4
515	Antegrade approach for percutaneous interventions of ostial superficial femoral artery: outcomes from a prospective series of diabetic patients presenting with critical limb ischemia. Cardiovascular Revascularization Medicine, 2012, 13, 20-24.	0.8	4
516	Newly available and recent advances in drug-eluting stents. Expert Review of Cardiovascular Therapy, 2013, 11, 555-566.	1.5	4
517	Ultrasound-Accelerated Thrombolysis and Extracorporeal Membrane Oxygenation in a Patient With Massive Pulmonary Embolism and Cardiac Arrest. Circulation: Cardiovascular Interventions, 2013, 6, e34-6.	3.9	4
518	Determinants of outcome in patients with chronic ischemic left ventricular dysfunction undergone percutaneous coronary interventions. BMC Cardiovascular Disorders, 2015, 15, 137.	1.7	4
519	Initial findings using the V8 hourglass-shaped valvuloplasty balloon for postdilatation in treating paravalvular leaks associated with transcatheter self-expanding aortic valve prosthesis. Catheterization and Cardiovascular Interventions, 2016, 87, 1306-1313.	1.7	4
520	TCT-88 Innovative Transcatheter Tricuspid Valve Repair System. Initial Outcomes from the First in Human Multi-Centre Study. Journal of the American College of Cardiology, 2016, 68, B36.	2.8	4
521	T-Stenting With Small Protrusion. JACC: Cardiovascular Interventions, 2016, 9, 1853-1854.	2.9	4
522	Prospective multicentre clinical performance evaluation of second and third generation zotarolimus-eluting stents to treat patients with bifurcated coronary lesions. Catheterization and Cardiovascular Interventions, 2016, 87, 15-22.	1.7	4

#	ARTICLE	IF	CITATIONS
523	Age-Related Differences in 1- and 12-Month Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation (from a Large Multicenter Data Repository). American Journal of Cardiology, 2016, 118, 1024-1030.	1.6	4
524	Bioresorbable scaffold failure for recurrent restenosis at multi-layered stent fracture. International Journal of Cardiology, 2016, 214, 360-361.	1.7	4
525	Transcatheter mitral valve implantation in rigid mitral annuloplasty rings: Potential differences between complete and incomplete rings. Catheterization and Cardiovascular Interventions, 2019, 93, E71-E74.	1.7	4
526	Transcatheter innovations in tricuspid regurgitation: Cardioband. Progress in Cardiovascular Diseases, 2019, 62, 482-485.	3.1	4
527	One-Year Outcomes of the TRI-REPAIR Study Assessing Cardioband Tricuspid Valve Reconstruction System for Patients with Functional Tricuspid Regurgitation. Journal of Cardiac Failure, 2019, 25, S11.	1.7	4
528	The Tricuspid Valve. JACC: Cardiovascular Interventions, 2019, 12, 179-181.	2.9	4
529	Outcome of Patients Undergoing Transcatheter Implantation of Aortic Valve With Previous Mitral Valve Prosthesis (OPTIMAL) Study. Canadian Journal of Cardiology, 2019, 35, 866-874.	1.7	4
530	Prevalence, Burden and Echocardiographic Features of Moderate to Severe Tricuspid Regurgitation: Insights from a Tertiary Referral Center. Structural Heart, 2019, 3, 123-131.	0.6	4
531	Looking Toward the Post-TAVR Period and Keeping Options Open for EasyÂCoronary Access. JACC: Cardiovascular Interventions, 2020, 13, 951-953.	2.9	4
532	Impact of body mass index on outcomes in patients undergoing transfemoral transcatheter aortic valve implantation. JTCVS Open, 2021, 6, 26-36.	0.5	4
533	Transcatheter Tricuspid Valve Intervention in Patients With Previous Left Valve Surgery. Canadian Journal of Cardiology, 2021, 37, 1094-1102.	1.7	4
534	Restenosis patterns after bioresorbable vascular scaffold implantation: Angiographic substudy of the <scp>GHOST</scp>â€<scp>EU</scp> registry. Catheterization and Cardiovascular Interventions, 2018, 92, 276-282.	1.7	4
535	MÃs herramientas para una necesidad no cubierta: nuevas opciones para el tratamiento percutÃneo de la insuficiencia tricuspÃdea. Revista Espanola De Cardiologia, 2019, 72, 991-993.	1.2	4
536	Impact of Absorb bioresorbable scaffold implantation technique on post-procedural quantitative coronary angiographic endpoints in ST-elevation myocardial infarction: a sub-analysis of the BVS STEMI STRATEGY-IT study. EuroIntervention, 2019, 15, 108-115.	3.2	4
537	Use of the Sideguard (Cappella) stent in bifurcation lesions: a real-world experience. EuroIntervention, 2012, 7, 1170-1180.	3.2	4
538	High-risk left main percutaneous coronary intervention supported by pressure-controlled intermittent coronary sinus occlusion. EuroIntervention, 2016, 12, e1437-e1437.	3.2	4
539	Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry. International Journal of Cardiology, 2022, 349, 31-38.	1.7	4
540	Severity of Functional Mitral Regurgitation on Admission for Acute Decompensated Heart Failure Predicts Longâ€Term Risk of Rehospitalization and Death. Journal of the American Heart Association, 2022, 11, e022908.	3.7	4

#	ARTICLE	IF	CITATIONS
541	Response to Letter Regarding Article, "Randomized Study of the Crush Technique Versus Provisional Side-Branch Stenting in True Coronary Bifurcations: The CACTUS (Coronary Bifurcations: Application) Trial." <i>Journal of the American College of Cardiology</i> , 2012, 60, 1002-1006.	0.7	3
542	Severity and prognostic localization of critical coronary artery stenoses. <i>Coronary Artery Disease</i> , 2012, 23, 455-459.	0.7	3
543	A review of thrombectomy devices. <i>Expert Review of Medical Devices</i> , 2012, 9, 513-520.	2.8	3
544	Iatrogenic perforation of the medial circumflex artery following femoral venous cannulation for transcatheter aortic valve replacement, presenting with retroperitoneal hematoma and successfully managed by percutaneous embolization and coiling. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 1002-1006.	1.7	3
545	Very Long-term Outcomes Following Drug-eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis: A Single Center Experience. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 24-33.	0.6	3
546	A case of Kawasaki's disease with extensive calcifications needing rotational atherectomy with a 2.5mm burr. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 248-251.	0.8	3
547	Hybrid percutaneous coronary revascularisation for a patient with left main bifurcation and extensive, diffuse coronary artery disease. <i>International Journal of Cardiology</i> , 2014, 173, e20-e22.	1.7	3
548	Why Do We Need Post-Dilation After Implantation of a Bioresorbable Vascular Scaffold Even for a Soft Lesion?. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1070-1072.	2.9	3
549	TCT-743 To Predilate or To Not Predilate In Transcatheter Aortic Valve Implantation? Single-Center Experience With Self-Expandable CoreValve Revalving System. <i>Journal of the American College of Cardiology</i> , 2014, 64, B217-B218.	2.8	3
550	Strategy for optimal side-branch positioning of bioresorbable vascular scaffolds in dedicated 2-stent techniques: Insights from optical coherence tomography. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 298-300.	0.8	3
551	Comparison of 2-year outcomes between zotarolimus-eluting and everolimus-eluting new-generation cobalt-chromium alloy stents in real-world diabetic patients. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, E11-8.	1.7	3
552	In-Scaffold Restenosis in a Previous Left Main Bifurcation Lesion Treated With Bioresorbable Scaffold V-Stenting. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, e7-e10.	2.9	3
553	Successful implantation of a second-generation aortic valve in severe aortic regurgitation secondary to a traumatic cusp lesion. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 429-431.	0.8	3
554	Excimer laser facilitated coronary angioplasty of a heavy calcified lesion treated with bioresorbable scaffolds. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e149-e150.	1.5	3
555	Very Late Restenosis After Bioresorbable Scaffold Implantation Due to Simultaneous External Compression of the Scaffold and Intrastent Tissue Growth. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, e15-e17.	2.9	3
556	A Case of Very Late (3 Years) Transcatheter Heart Valve Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, e83-e84.	2.9	3
557	Multimodality evaluation of percutaneous closure of coronary fistula using AMPLATZER Vascular Plug IV. <i>International Journal of Cardiology</i> , 2016, 225, 381-383.	1.7	3
558	A super high-pressure balloon solution for a non-dilatable in-stent restenosis. <i>International Journal of Cardiology</i> , 2016, 203, 357-359.	1.7	3

#	ARTICLE	IF	CITATIONS
559	Hypertrophic Left Ventricle With Small Cavity and Severe Aortic Angulation. JACC: Cardiovascular Interventions, 2018, 11, e29-e30.	2.9	3
560	A comparison of the fully repositionable and retrievable Boston Lotus and direct flow medical valves for the treatment of severe aortic stenosis: A single center experience. Catheterization and Cardiovascular Interventions, 2018, 91, 966-974.	1.7	3
561	Subclinical Leaflet Thrombosis After Transcatheter Mitral Valve-in-Ring Implantation. JACC: Cardiovascular Interventions, 2018, 11, e105-e106.	2.9	3
562	Temporal trends in procedural death and need for urgent open surgery during transcatheter aortic valve replacement: A single, high-volume center 10-year experience. International Journal of Cardiology, 2019, 293, 80-83.	1.7	3
563	Transcatheter Treatment of Pure Aortic Regurgitation in a Horizontal Aorta Complicated by Valve Embolization and Aortic Dissection. Cardiovascular Revascularization Medicine, 2019, 20, 535-536.	0.8	3
564	Comparison of Incidence and Outcomes of Cardiogenic Shock Complicating Posterior (Inferior) Versus Anterior ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2020, 125, 1013-1019.	1.6	3
565	ONE MONTH DUAL ANTIPLATELET THERAPY IN HIGH BLEEDING RISK PATIENTS: PRIMARY RESULTS FROM THE ONYX ONE CLEAR STUDY. Journal of the American College of Cardiology, 2020, 75, 1097.	2.8	3
566	The effect of transcatheter aortic valve implantation approaches on mortality. Catheterization and Cardiovascular Interventions, 2021, 97, 1462-1469.	1.7	3
567	Direct oral anticoagulants in patients with atrial fibrillation and bioprosthetic valve replacement: A meta-analysis. Catheterization and Cardiovascular Interventions, 2021, 98, E1007-E1016.	1.7	3
568	Imaging for transcatheter native tricuspid valve intervention: patient selection, procedural planning and interventional guidance. Minerva Cardiology and Angiology, 2021, 69, 707-719.	0.7	3
569	Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1-month dual antiplatelet therapy following <scp>PCI</scp>: Analysis from the <scp>Onyx ONE</scp> clear study. Catheterization and Cardiovascular Interventions, 2022, 99, 583-592.	1.7	3
570	Elective Double Stenting for Left Main Coronary Artery Bifurcation Lesions. , 2010, , 149-192.		3
571	Clinical outcomes following ^{off-label}-versus ^{established}-indications of bioresorbable scaffolds for the treatment of coronary artery disease in a real-world population. EuroIntervention, 2016, 11, 1475-1478.	3.2	3
572	Urinary neutrophil gelatinase-associated lipocalin as a predictor of acute kidney injury after transcatheter aortic valve implantation. Hellenic Journal of Cardiology, 2014, 55, 77-9.	1.0	3
573	Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation. American Journal of Cardiology, 2022, 172, 90-97.	1.6	3
574	Transcatheter edge-to-edge repair of the tricuspid valve: The US experience. Catheterization and Cardiovascular Interventions, 2022, 99, 1859-1866.	1.7	3
575	Sex Differences in Infective Endocarditis After Transcatheter Aortic Valve Replacement. Canadian Journal of Cardiology, 2022, 38, 1418-1425.	1.7	3
576	Scimitar syndrome. Journal of Cardiovascular Medicine, 2011, 12, 176-177.	1.5	2

#	ARTICLE	IF	CITATIONS
577	Disease Progression Is as Important as Culprit Lesion Treatment. Journal of the American College of Cardiology, 2012, 59, 800-801.	2.8	2
578	TCT-847 Adequate choice of the post dilatation balloon size in patients undergoing TAVI based on the CT scan analysis. Journal of the American College of Cardiology, 2012, 60, B245-B246.	2.8	2
579	Unanticipated Pseudocoarctation Highlights the Importance of Visualizing Aortic Arch Anatomy Before Transfemoral Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2014, 7, 631-633.	3.9	2
580	Delayed Disruption of a Bioresorbable Vascular Scaffold. JACC: Cardiovascular Imaging, 2014, 7, 845-847.	5.3	2
581	TCT-430 Ancillary radial versus femoral/brachial approach to reduce vascular complications in complex coronary, peripheral and structural interventions. Preliminary results of a study from the Italian Radial Club. Journal of the American College of Cardiology, 2015, 66, B175-B176.	2.8	2
582	1-Year Follow-Up Optical Coherence Tomography of a Hybrid Neocarina After T-Stenting With Small Protrusion Technique Using a Bioresorbable Vascular Scaffold and a Metallic Stent. JACC: Cardiovascular Interventions, 2015, 8, e101-e103.	2.9	2
583	Successful Repositioning of a Direct Flow Medical 25-mm Valve due to Acute Occlusion of Right Coronary Artery During Transcatheter Aortic Valve Replacement Procedure. JACC: Cardiovascular Interventions, 2015, 8, e33-e34.	2.9	2
584	Two-Year Follow-Up OCT Images of Bifurcation Lesions Treated With Bioresorbable Vascular Scaffolds. JACC: Cardiovascular Imaging, 2015, 8, 617-618.	5.3	2
585	Provisional hybrid stent Strategy utilizing bioresorbable vascular scaffold and drug-eluting metal stent: stenting and small protrusion technique. Catheterization and Cardiovascular Interventions, 2015, 86, 682-685.	1.7	2
586	Impact and natural history of postprocedural aortic regurgitation on early and midterm mortality following transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis. Journal of Cardiovascular Medicine, 2015, 16, 286-295.	1.5	2
587	Severe Neointimal Hyperplasia of Neoplastic Carina Following Bioresorbable Scaffold Implantation Using T-Stenting and Small Protrusion Technique. JACC: Cardiovascular Interventions, 2015, 8, e207-e209.	2.9	2
588	TCT-506 Coronary sinus reduction improves myocardial perfusion reserve index assessed by dipyridamole stress cardiac magnetic resonance.. Journal of the American College of Cardiology, 2016, 68, B203.	2.8	2
589	TCT-419 Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds implantation: the PSP score. Journal of the American College of Cardiology, 2016, 68, B169-B170.	2.8	2
590	Clinical outcomes following bioresorbable scaffold implantation in small vessels. International Journal of Cardiology, 2016, 207, 59-61.	1.7	2
591	Resource utilization for transfemoral transcatheter aortic valve replacement: An international comparison. Catheterization and Cardiovascular Interventions, 2016, 87, 145-151.	1.7	2
592	Case illustration of the difference between bench test and in-vivo scaffold fracture thresholds. International Journal of Cardiology, 2016, 225, 20-22.	1.7	2
593	OCT Images of Longitudinal Deformation Following BVS Implantation in the Right Coronary Ostium. JACC: Cardiovascular Imaging, 2016, 9, 751-752.	5.3	2
594	A Novel Technique for Prosthetic Valve Retrieval After Transcatheter Aortic Valve Embolization. Canadian Journal of Cardiology, 2017, 33, 951.e1-951.e3.	1.7	2

#	ARTICLE	IF	CITATIONS
595	Advances in percutaneous interventional therapies: the tricuspid valve. <i>Future Cardiology</i> , 2017, 13, 239-245.	1.2	2
596	Use of a parallel stiff wire to facilitate percutaneous Impella RP ventricular assist device positioning. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 54-55.	0.8	2
597	Bioresorbable Vascular Scaffolds and Very Late Scaffold Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 745-746.	2.9	2
598	Intrastent Hematoma After Pre-Dilatation for 17-Month Restenosis of Polytetrafluoroethylene-Covered Stent. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, e213-e215.	2.9	2
599	Diagnostic Accuracy of Microcatheter Derived Fractional Flow Reserve. <i>American Journal of Cardiology</i> , 2019, 124, 183-189.	1.6	2
600	â€œMatryoshkaâ€•Valve-in-Valve-in-Valve Transcatheter Aortic Valve Replacement and Do-It-Yourself Catheter to Cross Aortic Valve Bioprosthesis Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, e97-e100.	2.9	2
601	Complementary Assessment by Hybrid Intravascular Ultrasound-Optical Coherence Tomography Catheter After Implantation of a New-Generation Drug-Eluting Stent. <i>Circulation Journal</i> , 2021, 85, 2119.	1.6	2
602	Zero-Contrast Transcatheter Aortic Valve-in-Valve Implantation Using Intravascular Ultrasound to Evaluate Coronary Obstruction Risk. <i>Circulation Journal</i> , 2021, 86, 168.	1.6	2
603	Comments on the article by Routledge et al â€œThree-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II)â€• <i>EuroIntervention</i> , 2010, 5, 875-876.	3.2	2
604	Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry. <i>EuroIntervention</i> , 2013, 9, 803-808.	3.2	2
605	Transcatheter mitral valve repair with MitraClip in a large real-world experience: lessons from Germany. <i>EuroIntervention</i> , 2019, 14, 1716-1719.	3.2	2
606	The impact of the use of bioresorbable vascular scaffolds and drug-coated balloons in coronary bifurcation lesions. <i>Egyptian Heart Journal</i> , 2019, 71, 31.	1.2	2
607	Rediscovered and Unforgotten: Transcatheter Interventions for the Treatment of Severe Tricuspid Valve Regurgitation. <i>US Cardiology Review</i> , 0, 15, .	0.5	2
608	Percutaneous treatment of iatrogenic left main ostial stenosis: after a Bentall operation. <i>Texas Heart Institute Journal</i> , 2012, 39, 144-5.	0.3	2
609	Prevalence, Characteristics, and Impact of Frailty in Patients with Functional Tricuspid Regurgitation. <i>International Heart Journal</i> , 2021, 62, 1280-1286.	1.0	2
610	Long-Term Intracoronary Structural and Vasomotor Assessment of the ABSORB Bioresorbable Vascular Scaffold. <i>American Journal of Cardiology</i> , 2022, , .	1.6	2
611	Minimal Acute Recoil Following Bioresorbable Scaffold Implantation in Fibrocalcific Lesion Detected by Optical Frequency-Domain Imaging. <i>Journal of Invasive Cardiology</i> , 2016, 28, E34-6.	0.4	2
612	Implementation of a Low Frame-Rate Protocol and Noise-Reduction Technology to Minimize Radiation Dose in Transcatheter Aortic Valve Replacement. <i>Journal of Invasive Cardiology</i> , 2018, 30, 169-175.	0.4	2

#	ARTICLE	IF	CITATIONS
613	Pacemaker-Related Complications in Patients Undergoing Transcatheter Aortic Valve Implantation: A Single-Center Experience. <i>Journal of Invasive Cardiology</i> , 2020, 32, E362-E369.	0.4	2
614	Malignant ST segment elevation. <i>European Heart Journal</i> , 2008, 29, 2448-2448.	2.2	1
615	Bimodal distribution of angiographic measures of restenosis: what does it mean?. <i>Heart</i> , 2009, 95, 1556-1558.	2.9	1
616	Anomalous left coronary artery origin from the pulmonary artery: an unusual late presentation of Bland-White syndrome. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 719-721.	1.5	1
617	Sandwich Stenting to Treat an Ostial Left Main Narrowing Following Transcatheter Aortic Valve Implantation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 1220-1222.	0.6	1
618	TCT-793 Effects of Preoperative Tricuspid Regurgitation on Mitral Regurgitation Treatment with the MitraClip Device in High-Risk Patients. <i>Journal of the American College of Cardiology</i> , 2012, 60, B231.	2.8	1
619	TCT-797 Transcatheter Mitral Valve-in-Valve / Valve-in-Ring Implantations For Degenerative Post Surgical Valves: Results From The Global Valve-in-Valve Registry. <i>Journal of the American College of Cardiology</i> , 2012, 60, B232.	2.8	1
620	Renal denervation in a patient with two renal accessory arteries: A case report. <i>Blood Pressure</i> , 2013, 22, 325-328.	1.5	1
621	TCT-432 Bioresorbable Vascular Scaffolds in Complex Coronary Lesions. <i>Journal of the American College of Cardiology</i> , 2013, 62, B133-B134.	2.8	1
622	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1832.	2.8	1
623	Aortic regurgitation after transcatheter aortic valve implantation. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1089-1092.	1.5	1
624	Paclitaxel-eluting balloons or paclitaxel-eluting stents for the treatment of small-vessel coronary artery disease?. <i>Interventional Cardiology</i> , 2013, 5, 137-140.	0.0	1
625	TCT-702 Multicenter Assessment of TAVR in Failed Aortic Bioprostheses: Evaluation of Implantation Depth and Association with Elevated Post-Procedural Gradients in SAPIEN vs. CoreValve Valve-in-Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2014, 64, B206.	2.8	1
626	Bicuspid aortic valves and TAVI: is it still an exclusion criterion? State of the art and open issues. <i>Interventional Cardiology</i> , 2015, 7, 381-388.	0.0	1
627	Transcatheter aortic valve implantation with a Direct Flow Medical valve in a patient with severe aortic regurgitation due to degenerated aortic stentless bioprosthesis. <i>International Journal of Cardiology</i> , 2015, 182, 267-270.	1.7	1
628	Acute heart failure management in a young patient requiring complex left main percutaneous coronary intervention, Impella 2.5 and transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2015, 180, 199-202.	1.7	1
629	Late-acquired scaffold malapposition and discontinuity that may be attributable to pathological coronary ectasia: Insights from optical coherence tomography. <i>International Journal of Cardiology</i> , 2015, 186, 136-138.	1.7	1
630	Transaortic valve implantation with the direct flow medical valve in an emergency situation of post-valvuloplasty severe aortic regurgitation. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 317-319.	0.8	1

#	ARTICLE	IF	CITATIONS
631	TCT-517 Long term clinical outcome following Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-stent Restenosis: a Multicenter Italian Experience. Journal of the American College of Cardiology, 2015, 66, B211.	2.8	1
632	TCT-521 Clinical outcomes after bioresorbable scaffold implantation in patients with a high prevalence of complex lesions: the Milan experience. Journal of the American College of Cardiology, 2015, 66, B213.	2.8	1
633	TCT-436 Multi-Center, Post-marketing Evaluation of the Elixir DESolve® Novolimus Eluting Bioresorbable Coronary Stent System: 6-month Results from the DESolve PMCF Study. Journal of the American College of Cardiology, 2016, 68, B176.	2.8	1
634	TCT-678 Incidence, Predictors and Clinical Outcomes of Coronary Obstruction Following Transcatheter Aortic Valve Implantation for Degenerative Bioprosthetic Surgical Valves: Insights from the VIVID Registry. Journal of the American College of Cardiology, 2016, 68, B274-B275.	2.8	1
635	TCT-351 Coronary sinus reducer implantation for the treatment of chronic refractory angina: a single center experience. Journal of the American College of Cardiology, 2016, 68, B144.	2.8	1
636	Is Multislice Computed Tomography a Feasible Option for Follow-Up of Complex Coronary Lesions Treated With Bioresorbable Scaffolds?. JACC: Cardiovascular Interventions, 2016, 9, 2578-2581.	2.9	1
637	A Tricky Percutaneous Paravalvular Leak Closure Two Years After Implantation of 3f Enable Sutureless Bioprosthetic Aortic Valve. Hellenic Journal of Cardiology, 2016, 57, 41-44.	1.0	1
638	Bioresorbable Scaffolds. JACC: Cardiovascular Interventions, 2016, 9, 1856-1857.	2.9	1
639	Incidence and significance of side branch occlusions following bioresorbable scaffold implantation for long left anterior descending artery lesions. International Journal of Cardiology, 2016, 222, 674-675.	1.7	1
640	Biolimus-Eluting Stent For de-novo coRonary artery disease in patiENTs with Diabetes mellituS. Journal of Cardiovascular Medicine, 2016, 17, 729-735.	1.5	1
641	A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions. Cardiovascular Revascularization Medicine, 2017, 18, S4-S9.	0.8	1
642	Paclitaxel eluting balloon plus spot bare metal stenting for diffuse and very long coronary disease. (PEB-long pilot study). Clinical Trials and Regulatory Science in Cardiology, 2017, 27, 1-7.	1.0	1
643	Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions. JACC: Cardiovascular Interventions, 2017, 10, 743-745.	2.9	1
644	Patent foramen ovale closure through inferior vena cava filter in a patient with deep venous thrombosis and recurrent ischemic events. Journal of Cardiovascular Medicine, 2017, 18, 828-830.	1.5	1
645	Dual Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation. JACC: Cardiovascular Interventions, 2017, 10, 1471-1472.	2.9	1
646	Long-term outcome of full plastic jacket treatment for bare metal in-stent restenosis. Cardiovascular Revascularization Medicine, 2017, 18, 139-140.	0.8	1
647	TCT-36 Delayed coronary obstruction after transcatheter aortic valve replacement. Journal of the American College of Cardiology, 2017, 70, B16.	2.8	1
648	Transcatheter Tricuspid Valve Intervention: Addressing an Unmet Clinical Need. Interventional Cardiology Clinics, 2018, 7, xiii-xiv.	0.4	1

#	ARTICLE	IF	CITATIONS
649	Bioresorbable vascular scaffold implantation for severely calcified lesions after excimer laser lesion preparation. Catheterization and Cardiovascular Interventions, 2018, 92, 1283-1288.	1.7	1
650	Should We Look Beyond the Annulus to Improve Prosthesis Size Selection?. JACC: Cardiovascular Interventions, 2019, 12, 1172-1174.	2.9	1
651	Valve-in-Valve Transcatheter Aortic Valve Implantation With Acurate neo for a Degenerated bio-Bentall. Cardiovascular Revascularization Medicine, 2020, 21, 18-20.	0.8	1
652	Sex Differences in Coronary Microvascular Dysfunction and Its Relationship With Outcome. JACC: Cardiovascular Interventions, 2020, 13, 1680-1682.	2.9	1
653	First in human evaluation of a novel Sirolimus-eluting ultra-high molecular weight bioresorbable scaffold: 9-, 24-and 36-months imaging and clinical results from the multi-center RENASCENT study. International Journal of Cardiology, 2020, 321, 48-53.	1.7	1
654	Understanding Iatrogenic Atrial Septal Defects. JACC: Cardiovascular Interventions, 2020, 13, 1554-1556.	2.9	1
655	RENASCENT III: First in Human Evaluation of the Novel Thin Strut MAGNITUDE Sirolimus-Eluting Ultra-High Molecular Weight MAGNITUDE Bioresorbable Scaffold: 9-Month Imaging and 2-Year Clinical Results. Circulation: Cardiovascular Interventions, 2021, 14, e010013.	3.9	1
656	Summary of Practice Considerations for Percutaneous Coronary Intervention of Left Main Bifurcation Disease. Heart International, 2020, 14, 69.	1.4	1
657	The drive towards standardised clinical study endpoints in transcatheter aortic valve interventions. EuroIntervention, 2016, 12, 298-300.	3.2	1
658	“Golden tube” with favorable vessel remodeling at four-year follow-up after bioresorbable vascular scaffold implantation for moderate to severe calcified lesions: Insights from intravascular imaging. Cardiology Journal, 2018, 25, 532-533.	1.2	1
659	Current Status and Future of Dedicated Bifurcation Stent Systems. , 2010, , 211-250.		1
660	Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term. Journal of Cardiovascular Medicine, 2022, 23, 278-280.	1.5	1
661	Clinical validation of a novel simplified offline tool for SYNTAX score calculation. Catheterization and Cardiovascular Interventions, 2022, 99, 1366-1368.	1.7	1
662	Recanalization of an occluded right coronary artery into the right internal mammary artery using a retrograde approach. Journal of Invasive Cardiology, 2007, 19, E73-5.	0.4	1
663	A case of an occlusive right coronary artery dissection after stent implantation: dilemmas and challenges. Journal of Invasive Cardiology, 2015, 27, E13-5.	0.4	1
664	Radiation Exposure and Contrast Agent Reduction During Transcatheter Aortic Valve Implantation: An Ongoing Experience. Journal of Invasive Cardiology, 2016, 28, 459-465.	0.4	1
665	First-in-man Percutaneous LAA Closure With an Amplatzer Amulet and TriGuard Embolic Protection Device in a Patient With LAA Thrombus. Journal of Invasive Cardiology, 2017, 29, E51-E52.	0.4	1
666	Prognostic value of tricuspid regurgitation. Reviews in Cardiovascular Medicine, 2022, 23, 076.	1.4	1

#	ARTICLE	IF	CITATIONS
667	Short-Term Outcomes After Transcatheter Aortic Valve Implantation With or Without Amyloidosis 2012 to 2019. American Journal of Cardiology, 2022, 169, 149-151.	1.6	1
668	Meta-Analysis of Relation Between Left Ventricular Dysfunction and Outcomes After Transcatheter Mitral Edge-to-Edge Repair. American Journal of Cardiology, 2022, 175, 88-96.	1.6	1
669	Monitoring conduction disturbances following TAVR: Feasibility study of early discharge using a novel telemetry patch. International Journal of Cardiology, 2022, , .	1.7	1
670	Transcatheter aortic valve-in-valve implantation to treat aortic Para-valvular regurgitation after TAVI. International Journal of Cardiology, 2022, , .	1.7	1
671	Expanding our horizons for the use of transcatheter self-expanding valves: what does the future hold?. Expert Review of Cardiovascular Therapy, 2022, 20, 497-501.	1.5	1
672	Clinical Predictors for Procedural Stroke and Implications for Embolic Protection Devices during TAVR: Results from the Multicenter Transcatheter Aortic Valve Replacement In-Hospital Stroke (TASK) Study. Journal of Personalized Medicine, 2022, 12, 1056.	2.5	1
673	An uncommon cause of aortic stenosis in an adult. Heart, 2005, 91, 1018-1018.	2.9	0
674	Cardiac Resynchronization Therapy (CRT) - a bridge to valve replacement surgery in â€™inoperableâ€™ LV dysfunction. Heart Rhythm, 2005, 2, S254.	0.7	0
675	Drug-eluting stents: What is the balance of risks and benefits?. Current Cardiovascular Risk Reports, 2007, 1, 279-283.	2.0	0
676	Impact of optimal medical therapy and percutaneous coronary intervention on patients with stable angina. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 92-93.	3.3	0
677	Reply on anomalous left coronary artery origin from the pulmonary artery (ALCAPA): an unusual late presentation of Blandâ€™Garlandâ€™White syndrome. Journal of Cardiovascular Medicine, 2010, 11, 556.	1.5	0
678	Bailout directional atherectomy for side branch salvage following subintimal recanalization of infragenicular arteries. Vasa - European Journal of Vascular Medicine, 2012, 41, 292-294.	1.4	0
679	Myocardial infarction in the young. International Journal of Cardiology, 2012, 159, 154-155.	1.7	0
680	TCT-370 Outcomes According to Sex Following Unprotected Left Main Stenting With Drug-Eluting Stents: The Milan Experience. Journal of the American College of Cardiology, 2012, 60, B106.	2.8	0
681	TCT-701 Two Year Outcomes Following Unprotected Left Main Stenting with First- vs. New-Generation Drug-Eluting Stents: The FINE Registry. Journal of the American College of Cardiology, 2012, 60, B204.	2.8	0
682	TCT-709 Predictors of Main Branch Restenosis Following Drug-eluting Stent Implantation in Patients with De Novo Unprotected Distal Left Main Bifurcation Coronary Lesions: The Milan and New-Tokyo (MITO) Registry. Journal of the American College of Cardiology, 2012, 60, B206.	2.8	0
683	TCT-799 MitraClip feasibility and efficacy in the context of unfavorable valve anatomy. Journal of the American College of Cardiology, 2012, 60, B232.	2.8	0
684	TCT-864 A comparison Of The Femoral And Radial Crossover Techniques For Vascular Access Management In Transcatheter Aortic Valve Implantation: The Milan Experience. Journal of the American College of Cardiology, 2012, 60, B250.	2.8	0

#	ARTICLE	IF	CITATIONS
685	TCT-900 High-degree Atrioventricular Block and Need for Permanent Pacemaker Implantation after Transcatheter and Surgical Aortic Valve Replacement. Journal of the American College of Cardiology, 2012, 60, B262.	2.8	0
686	Stent Thrombosis After Kissing Balloons. JACC: Cardiovascular Interventions, 2012, 5, 1290-1291.	2.9	0
687	AS-170 Outcomes Following Unprotected Left Main Stenting with Newer Generation Drug-Eluting Stents: The Milan Experience. American Journal of Cardiology, 2012, 109, S85.	1.6	0
688	AS-124 Outcomes Following Transcatheter Aortic Valve Implantation Comparing Edwards SAPIEN [®] , [®] XT And Medtronic CoreValve ReValving System [®] Devices: Results from the Milan Registry. American Journal of Cardiology, 2012, 109, S2-S3.	1.6	0
689	AS-298 VARC Outcomes Following Transcatheter Aortic Valve Implantation With Both Edwards SAPIEN [®] , [®] XT And Medtronic CoreValve ReValving System [®] Devices: Results from the Milan Registry. American Journal of Cardiology, 2012, 109, S3.	1.6	0
690	TCT-759 Correlates for Device Malposition during Aortic Valve-in-Valve Implantation: Insights from the Global Valve-in-Valve Registry. Journal of the American College of Cardiology, 2013, 62, B231.	2.8	0
691	TCT-812 The Impact of Renal Function on Long-term Mortality in Unprotected Left Main Disease, Milan and New-Tokyo Registry. Journal of the American College of Cardiology, 2013, 62, B246.	2.8	0
692	TCT-465 Drug-Eluting Balloon in the Treatment of Instent Restenosis and Diffuse Coronary Artery Disease; Real World Experience from a Single Center Registry. Journal of the American College of Cardiology, 2013, 62, B142.	2.8	0
693	Reply. JACC: Cardiovascular Interventions, 2013, 6, 427-428.	2.9	0
694	TCT-572 Impact of calcium-deposit for left circumflex ostium narrowing after crossover stenting in distal left main bifurcation: An Intravascular Ultrasound Study in the Milan and Fukuyama Registry.. Journal of the American College of Cardiology, 2013, 62, B172-B173.	2.8	0
695	Selection of Medications to Prevent Stroke Among Individuals With Atrial Fibrillation. Current Treatment Options in Neurology, 2013, 15, 583-592.	1.8	0
696	Response to Letter Regarding Article, "Clinical Impact of Persistent Left Bundle-Branch Block After Transcatheter Aortic Valve Implantation With CoreValve ReValving System" • Circulation, 2013, 128, e444.	1.6	0
697	TCT-627 Comparison of Procedural Feasibility Between Bioresorbable Vascular Scaffold and New-generation Drug Eluting Stent in an All-comer Population. Journal of the American College of Cardiology, 2014, 64, B183.	2.8	0
698	TCT-284 Synergy of Drug Coated Balloons plus Second-generation Drug Eluting Stents in lesions with high risk for restenosis. Journal of the American College of Cardiology, 2014, 64, B82.	2.8	0
699	TCT-244 Real World 1-year Clinical Outcomes of Bioresorbable Vascular Scaffold Implanted in Diabetic Patients. Journal of the American College of Cardiology, 2014, 64, B72.	2.8	0
700	TCT-609 Comparison of one year outcomes in real world patients treated with a polymer free amphilius eluting coronary stent versus second generation everolimus eluting stents. Journal of the American College of Cardiology, 2014, 64, B178.	2.8	0
701	TCT-250 A Comparison of Cobalt-Chromium Alloy Stents: Zotarolimus-eluting and Everolimus-eluting in Patients with Diabetes. Journal of the American College of Cardiology, 2014, 64, B73.	2.8	0
702	TCT-277 Synergy of Drug Coated Balloons plus Second-generation Drug Eluting Stents versus Second-generation Drug Eluting Stents: A Propensity Matched Analysis. Journal of the American College of Cardiology, 2014, 64, B80-B81.	2.8	0

#	ARTICLE	IF	CITATIONS
703	TCT-466 Long-term outcomes following mini-crush versus culotte stenting for unprotected left main coronary artery disease: a substudy from the Milan and New-Tokyo (MITO) registry. Journal of the American College of Cardiology, 2015, 66, B191.	2.8	0
704	TCT-501 A propensity-matched study comparing overlapping bioresorbable scaffolds versus new generation everolimus eluting stents. Journal of the American College of Cardiology, 2015, 66, B205.	2.8	0
705	Simplifying the double kissing (DK) crush with the use of bioresorbable scaffolds. International Journal of Cardiology, 2015, 196, 139-142.	1.7	0
706	TCT-107 The DISCOVER Registry: 1 Year outcomes of a fully re-positionable and retrievable non-metallic transcatheter aortic valve in a real-world population. Journal of the American College of Cardiology, 2015, 66, B49-B50.	2.8	0
707	TCT-229 Safety and Efficacy of Rotational Atherectomy for the Treatment of Undilatable Underexpanded Stents Implanted in Calcific Lesions. Journal of the American College of Cardiology, 2016, 68, B93.	2.8	0
708	TCT-361 Targeting Transradial Approach: an Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of the American College of Cardiology, 2016, 68, B148.	2.8	0
709	TCT-652 Incidence, Predictors and Clinical Outcomes of Device Malposition Following Transcatheter Aortic Valve Implantation for Degenerative Bioprosthetic Surgical Valves: Insights from the VIVID Registry. Journal of the American College of Cardiology, 2016, 68, B264.	2.8	0
710	Illustration of the Resorption Process Between 2 Different Overlapping Bioresorbable Scaffolds. JACC: Cardiovascular Imaging, 2016, 9, 1469-1470.	5.3	0
711	Restored Physiological Vasomotion Imitating Intrascavfold Restenosis 3 Years After Bioresorbable Scaffold Implantation. Canadian Journal of Cardiology, 2016, 32, 1574.e9-1574.e10.	1.7	0
712	A coronary solution to manage a vascular peripheral obstruction post transcatheter aortic valve implantation. International Journal of Cardiology, 2016, 222, 827-829.	1.7	0
713	Valve-in-valve transcatheter aortic valve implantation overcoming hostile anatomy: Evolut R for the treatment of Mitroflow bioprosthesis dysfunction. Cardiovascular Intervention and Therapeutics, 2016, 31, 292-295.	2.3	0
714	Transarterial Endoleak Closure After Endovascular Thoracoabdominal Aneurysm Repair. Journal of Endovascular Therapy, 2016, 23, 220-224.	1.5	0
715	Vascular Healing of a False Lumen After Bioresorbable Scaffold Implantation. Circulation: Cardiovascular Interventions, 2016, 9, e003498.	3.9	0
716	CRT-100.78 A Hybrid Strategy With Bioresorbable Vascular Scaffolds And Drug Eluting Stents For Treating Complex Coronary Lesions. JACC: Cardiovascular Interventions, 2017, 10, S25.	2.9	0
717	TCT-580 Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Journal of the American College of Cardiology, 2017, 70, B240-B241.	2.8	0
718	Transfemoral Lotus Valve Implantation for Treatment of Postendocarditis Stentless Prosthesis Degeneration With Pure Aortic Regurgitation. Canadian Journal of Cardiology, 2017, 33, 1066.e17-1066.e18.	1.7	0
719	TCTAP A-059 Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary in Stent Restenosis: Long-term Clinical Outcomes of a Multicenter Italian Experience. Journal of the American College of Cardiology, 2017, 69, S31.	2.8	0
720	Reply. JACC: Cardiovascular Interventions, 2017, 10, 1275-1276.	2.9	0

#	ARTICLE	IF	CITATIONS
721	TCT-50 Impact of Anticoagulation Therapy on Valve Hemodynamic Deterioration Following Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2017, 70, B22.	2.8	0
722	Patient selection and percutaneous technique of unprotected left main revascularization. Catheterization and Cardiovascular Interventions, 2018, 92, 637-643.	1.7	0
723	Multimodality Imaging of a Very Late Thrombosis of a Sutureless Aortic Prosthesis. JACC: Cardiovascular Interventions, 2018, 11, e25-e26.	2.9	0
724	Ventricular septal defect and left ventricular outflow tract obstruction after transcatheter aortic valve implantation. Journal of Cardiovascular Medicine, 2018, 19, 181-182.	1.5	0
725	Severe Mitral Stenosis and Persistent Left Appendage Thrombosis. JACC: Cardiovascular Interventions, 2018, 11, e11-e13.	2.9	0
726	Different behaviors of bioresorbable vascular scaffold in different types of calcified lesion: Insights from intravascular imaging. Journal of Cardiology Cases, 2018, 17, 126-129.	0.5	0
727	Tricuspid regurgitation: from physiopathology to transcatheter interventions. Minerva Cardioangiologica, 2018, 66, 671-672.	1.2	0
728	Evolving Evidence for Cerebral Protection Devices in Transcatheter Aortic Valve Replacement. Cardiovascular Revascularization Medicine, 2018, 19, 735-736.	0.8	0
729	Different Behavior of Bioresorbable Vascular Scaffold and Metallic Stent With Positive Vessel Remodeling. Circulation Journal, 2018, 82, 1716-1717.	1.6	0
730	Expanding the Armamentarium to Tackle a Still Unmet Need: New Transcatheter Options for the Treatment of Tricuspid Regurgitation. Revista Espanola De Cardiologia (English Ed), 2019, 72, 991-993.	0.6	0
731	TCT-91 1-Year Outcomes From the Multicenter, Prospective Study With the Novel PASCAL Transcatheter Valve Repair System for Patients With Mitral Regurgitation in the CLASP Study. Journal of the American College of Cardiology, 2019, 74, B91.	2.8	0
732	TCT-274 A Prospective Multicenter Study to Assess the Long-Term Safety and Efficacy of Sirolimus-Coated Balloon in Treatment of In-Stent Restenosis in Unselected Real-World Patients. Journal of the American College of Cardiology, 2019, 74, B273.	2.8	0
733	TCT-745 Insights Into Sex Differences in Transfemoral Transcatheter Aortic Valve Implantation From 2007 to 2018: From the CENTER Collaboration, A Global Patient-Level Analysis of 12,381 Patients. Journal of the American College of Cardiology, 2019, 74, B731.	2.8	0
734	Six-month Outcomes from the Multicenter, Prospective Study with the Novel PASCAL Transcatheter Valve Repair System for Patients with Mitral Regurgitation in the CLASP Study. Journal of Cardiac Failure, 2019, 25, S6.	1.7	0
735	Drug-Coated Balloons: Lessons from the Real World. , 2019, , 189-201.		0
736	Stent Use After Drug-Coated Balloons. , 2019, , 203-208.		0
737	Supra-Annular Transcatheter Aortic Valve Position May Correct Annular Under-Expansion Due to Valvular Asymmetry. Circulation Journal, 2019, 83, 691.	1.6	0
738	The "crown" syndrome of delayed coronary obstruction after transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine, 2019, 20, 81-83.	0.8	0

#	ARTICLE	IF	CITATIONS
739	TAVR in Patients With LeftÂVentricularÂThrombus. JACC: Case Reports, 2020, 2, 1106-1108.	0.6	0
740	Transcatheter aortic valve replacement: potential use in lower-risk aortic stenosis. Expert Review of Cardiovascular Therapy, 2020, 18, 723-731.	1.5	0
741	COMPARISON OF TRANSFEMORAL VERSUS TRANSRADIAL SECONDARY ACCESS IN TRANSCATHETER AORTIC VALVE REPLACEMENT. Journal of the American College of Cardiology, 2020, 75, 1166.	2.8	0
742	Editorial: Percutaneous Mitral Valve Interventions (Repair): Current Indications and Future Perspectives. Frontiers in Cardiovascular Medicine, 2020, 7, 581109.	2.4	0
743	A COMPARISON OF OUTCOMES OF PATIENTS WITH SEVERE TRICUSPID REGURGITATION UNDERGOING ISOLATED SURGICAL REPAIR VS. REPLACEMENT: A META-ANALYSIS AND META-REGRESSION. Journal of the American College of Cardiology, 2020, 75, 2146.	2.8	0
744	Reply. JACC: Cardiovascular Interventions, 2021, 14, 585-586.	2.9	0
745	Surgical feasibility of ascending aorta manipulation after transcatheter aortic valve implantation: a computed tomography theoretical analysis. EuroIntervention, 2021, 16, e1533-e1540.	3.2	0
746	Editorial: Transcatheter Aortic Valve Implantationâ€”Current Challenges and Future Directions. Frontiers in Cardiovascular Medicine, 2021, 8, 748376.	2.4	0
747	Tricuspid Valve Morphology in Transcatheter Interventions. JACC: Cardiovascular Interventions, 2021, 14, 2271-2273.	2.9	0
748	Stents farmacolÃ³gicos para lesÃµes em bifurcaÃ§Ãµes: outra indicaÃ§Ã£o nÃ£o aprovada (off-label) com resultados superiores aos dos stents nÃ£o-farmacolÃ³gicos. Revista Brasileira De Cardiologia Invasiva, 2008, 16, 389-391.	0.1	0
749	How to Select the Most Appropriate Patient and Lesion to be Treated with a Coronary Bioresorbable Vascular Scaffold. Interventional Cardiology Review, 2013, 8, 90.	1.6	0
750	How should I treat aortic valvular stenosis in a high-risk surgical patient who previously received a stent in the ostial left main?. EuroIntervention, 2013, 9, 1004-1007.	3.2	0
751	How should I treat a coronary bifurcation wide-neck aneurysm?. EuroIntervention, 2014, 9, 1364-1367.	3.2	0
752	Drug-Eluting Stent Thrombosis: An oversensationalized but unresolved problem?. Monaldi Archives for Chest Disease, 2007, 68, 1-5.	0.6	0
753	Preprocedural planning and implantation of a transcatheter aortic valve without the use of contrast agent. EuroIntervention, 2016, 11, 1433-1433.	3.2	0
754	Difficult Cases and Complications from the Catheterization Laboratory: Case 1. , 2017, , 77-84.		0
755	How should I treat recurrent restenosis with underexpanded multilayered struts after repeated complex bifurcation stenting?. EuroIntervention, 2017, 12, 1795-1798.	3.2	0
756	Experimental validation of TMVR technologies: a bumpy road with the risk of getting lost in translation. EuroIntervention, 2017, 13, e1376-e1378.	3.2	0

#	ARTICLE	IF	CITATIONS
757	Severe aortic regurgitation due to a Lunderquist Extra-Stiff Wire Guide during transcatheter aortic valve implantation. <i>Cardiology Journal</i> , 2018, 25, 642-643.	1.2	0
758	The future of percutaneous tricuspid valve interventions. <i>Minerva Cardioangiologica</i> , 2018, 66, 735-743.	1.2	0
759	Variation in vessel healing response after implantation of two different poly-L-lactic acid bioresorbable scaffolds: insights from optical coherence tomography. <i>EuroIntervention</i> , 2018, 14, e1304-e1305.	3.2	0
760	The changing landscape of interventional cardiology. <i>Aging</i> , 2019, 11, 2914-2915.	3.1	0
761	Will the PARTNER 3 Low Risk Trial change my practice?. <i>EuroIntervention</i> , 2019, 15, e1077-e1080.	3.2	0
762	Transcatheter Annular Approaches for Tricuspid Regurgitation (Cardioband and Others). <i>Interventional Cardiology Clinics</i> , 2022, 11, 67-80.	0.4	0
763	Risk Assessment of Coronary Artery Obstruction Following Valve-in-Valve TAVR Using Dual IVUS Ostial Evaluation Technique. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2527-2529.	2.9	0
764	Meta-Analysis of 5-Year Risk of All-Cause Death or Stroke After Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement. <i>American Journal of Cardiology</i> , 2022, , .	1.6	0
765	Bifurcation stenting with drug-eluting stents. <i>Indian Heart Journal</i> , 2007, 59, B99-104.	0.5	0
766	Transseptal access for MitraClip® procedures using surgical diathermy under echocardiographic guidance. <i>EuroIntervention</i> , 2012, , .	3.2	0
767	Transfemoral Treatment of a Paraprosthetic Mitral Leak and Mitral Bioprosthesis Failure Complicated by Embolization of In-Situ Vascular Plug. <i>Journal of Heart Valve Disease</i> , 2015, 24, 653-5.	0.5	0
768	Saphenous Vein Graft Aneurysm 10 Years After Paclitaxel-Eluting Stent Implantation. <i>Journal of Invasive Cardiology</i> , 2017, 29, E63.	0.4	0
769	Thrombolysis-Guided Primary Percutaneous Coronary Intervention. <i>Journal of Invasive Cardiology</i> , 2018, 30, E154.	0.4	0
770	Paclitaxel Drug-Coated Balloon for the Treatment of De Novo Small-Vessel and Restenotic Coronary Artery Lesions: 12-Month Results of the Prospective, Multicenter, Single-Arm PREVAIL Study. <i>Journal of Invasive Cardiology</i> , 2021, 33, E863-E869.	0.4	0
771	299â€³3-Year results of STEMI patients treated with a pre-specified BVS implantation strategy: BVS SYTEMI strategy-it long term. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
772	90â€³Annular size and interaction with trans-catheter aortic valves for the treatment of severe bicuspid aortic valve stenosis: insights from the beat registry. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
773	464â€³Implantation of contemporary transcatheter aortic valves in small aortic annuli: the international multicentre TAVI-SMALL 2 registry. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
774	Timing of Stent Thrombosis After 1-Month Discontinuation of Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1963-1965.	2.8	0